
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="8E59BBE692607B133ABBE6000DBC7E4B.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="elsevierwt">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11004588/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of the American College of Cardiology">
<meta name="citation_title" content="Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis">
<meta name="citation_author" content="Adam Ioannou">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Francesco Cappelli">
<meta name="citation_author_institution" content="Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy">
<meta name="citation_author" content="Michele Emdin">
<meta name="citation_author_institution" content="Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Pisa, Italy">
<meta name="citation_author_institution" content="Fondazione Toscana Gabriele Monasterio, Pisa, Italy">
<meta name="citation_author" content="Christian Nitsche">
<meta name="citation_author_institution" content="Division of Cardiology, Department of Internal Medicine, Medical University of Vienna, Vienna, Austria">
<meta name="citation_author" content="Simone Longhi">
<meta name="citation_author_institution" content="Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy">
<meta name="citation_author" content="Ahmad Masri">
<meta name="citation_author_institution" content="OHSU Center for Hypertrophic Cardiomyopathy and Amyloidosis, Portland, Oregon, USA">
<meta name="citation_author" content="Alberto Cipriani">
<meta name="citation_author_institution" content="Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy">
<meta name="citation_author_institution" content="Cardiology Unit, University Hospital Padua, Padua, Italy">
<meta name="citation_author" content="Mattia Zampieri">
<meta name="citation_author_institution" content="Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy">
<meta name="citation_author" content="Federica Colio">
<meta name="citation_author_institution" content="Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy">
<meta name="citation_author" content="Michael Poledniczek">
<meta name="citation_author_institution" content="Division of Cardiology, Department of Internal Medicine, Medical University of Vienna, Vienna, Austria">
<meta name="citation_author" content="Aldostefano Porcari">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author_institution" content="Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy">
<meta name="citation_author" content="Yousuf Razvi">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Alberto Aimo">
<meta name="citation_author_institution" content="Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Pisa, Italy">
<meta name="citation_author_institution" content="Fondazione Toscana Gabriele Monasterio, Pisa, Italy">
<meta name="citation_author" content="Giuseppe Vergaro">
<meta name="citation_author_institution" content="Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Pisa, Italy">
<meta name="citation_author_institution" content="Fondazione Toscana Gabriele Monasterio, Pisa, Italy">
<meta name="citation_author" content="Laura De Michieli">
<meta name="citation_author_institution" content="Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy">
<meta name="citation_author" content="Muhammad U Rauf">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Rishi K Patel">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Eugenia Villanueva">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Yael Lustig">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Lucia Venneri">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Ana Martinez-Naharro">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Helen Lachmann">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Ashutosh Wechalekar">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Carol Whelan">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Aviva Petrie">
<meta name="citation_author_institution" content="University College London, Biostatistics Unit, UCL Eastman Dental Institute, London, United Kingdom">
<meta name="citation_author" content="Philip N Hawkins">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Scott Solomon">
<meta name="citation_author_institution" content="Cardiovascular Division, Brigham and Women&#x27;s Hospital, Harvard Medical School, Boston, Massachusetts, USA">
<meta name="citation_author" content="Julian D Gillmore">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_author" content="Marianna Fontana">
<meta name="citation_author_institution" content="National Amyloidosis Centre, University College London, London, United Kingdom">
<meta name="citation_publication_date" content="2024 Apr 9">
<meta name="citation_volume" content="83">
<meta name="citation_issue" content="14">
<meta name="citation_firstpage" content="1276">
<meta name="citation_doi" content="10.1016/j.jacc.2023.12.036">
<meta name="citation_pmid" content="38530684">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11004588/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11004588/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11004588/pdf/main.pdf">
<meta name="description" content="Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cardiomyopathy. The clinical course varies among individuals and there are no established measures to assess disease progression. The goal of this study was to assess the prognostic ...">
<meta name="og:title" content="Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cardiomyopathy. The clinical course varies among individuals and there are no established measures to assess disease progression. The goal of this study was to assess the prognostic ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11004588/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11004588">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1016/j.jacc.2023.12.036"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/main.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11004588%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/11004588/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/11004588/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11004588/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-elsevierwt.png" alt="Elsevier Sponsored Documents logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Elsevier Sponsored Documents" title="Link to Elsevier Sponsored Documents" shape="default" href="https://doi.org/10.1016/j.jacc.2023.12.036" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Am Coll Cardiol</button></div>. 2024 Apr 9;83(14):1276–1291. doi: <a href="https://doi.org/10.1016/j.jacc.2023.12.036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1016/j.jacc.2023.12.036</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22J%20Am%20Coll%20Cardiol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Am%20Coll%20Cardiol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Am%20Coll%20Cardiol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Am%20Coll%20Cardiol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ioannou%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Adam Ioannou</span></a><div hidden="hidden" id="id1">
<h3>
<span class="name western">Adam Ioannou</span>, <span class="degrees">MBBS, BSc</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ioannou%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Adam Ioannou</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cappelli%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Francesco Cappelli</span></a><div hidden="hidden" id="id2">
<h3>
<span class="name western">Francesco Cappelli</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>b</sup>Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cappelli%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Francesco Cappelli</span></a>
</div>
</div>
<sup>b</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Emdin%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Michele Emdin</span></a><div hidden="hidden" id="id3">
<h3>
<span class="name western">Michele Emdin</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>c</sup>Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Pisa, Italy</div>
<div class="p">
<sup>d</sup>Fondazione Toscana Gabriele Monasterio, Pisa, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Emdin%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Michele Emdin</span></a>
</div>
</div>
<sup>c,</sup><sup>d</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nitsche%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Christian Nitsche</span></a><div hidden="hidden" id="id4">
<h3>
<span class="name western">Christian Nitsche</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>e</sup>Division of Cardiology, Department of Internal Medicine, Medical University of Vienna, Vienna, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nitsche%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Christian Nitsche</span></a>
</div>
</div>
<sup>e</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Longhi%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Simone Longhi</span></a><div hidden="hidden" id="id5">
<h3>
<span class="name western">Simone Longhi</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>f</sup>Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Longhi%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Simone Longhi</span></a>
</div>
</div>
<sup>f</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Masri%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Ahmad Masri</span></a><div hidden="hidden" id="id6">
<h3>
<span class="name western">Ahmad Masri</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>g</sup>OHSU Center for Hypertrophic Cardiomyopathy and Amyloidosis, Portland, Oregon, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Masri%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahmad Masri</span></a>
</div>
</div>
<sup>g</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cipriani%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Alberto Cipriani</span></a><div hidden="hidden" id="id7">
<h3>
<span class="name western">Alberto Cipriani</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>h</sup>Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy</div>
<div class="p">
<sup>i</sup>Cardiology Unit, University Hospital Padua, Padua, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cipriani%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alberto Cipriani</span></a>
</div>
</div>
<sup>h,</sup><sup>i</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zampieri%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Mattia Zampieri</span></a><div hidden="hidden" id="id8">
<h3>
<span class="name western">Mattia Zampieri</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>b</sup>Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zampieri%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mattia Zampieri</span></a>
</div>
</div>
<sup>b</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Colio%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Federica Colio</span></a><div hidden="hidden" id="id9">
<h3>
<span class="name western">Federica Colio</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>b</sup>Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Colio%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Federica Colio</span></a>
</div>
</div>
<sup>b</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Poledniczek%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Michael Poledniczek</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Michael Poledniczek</span></h3>
<div class="p">
<sup>e</sup>Division of Cardiology, Department of Internal Medicine, Medical University of Vienna, Vienna, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Poledniczek%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Michael Poledniczek</span></a>
</div>
</div>
<sup>e</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Porcari%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Aldostefano Porcari</span></a><div hidden="hidden" id="id11">
<h3>
<span class="name western">Aldostefano Porcari</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">
<sup>j</sup>Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Porcari%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Aldostefano Porcari</span></a>
</div>
</div>
<sup>a,</sup><sup>j</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Razvi%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Yousuf Razvi</span></a><div hidden="hidden" id="id12">
<h3>
<span class="name western">Yousuf Razvi</span>, <span class="degrees">MBChB, BSc</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Razvi%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yousuf Razvi</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aimo%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Alberto Aimo</span></a><div hidden="hidden" id="id13">
<h3>
<span class="name western">Alberto Aimo</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>c</sup>Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Pisa, Italy</div>
<div class="p">
<sup>d</sup>Fondazione Toscana Gabriele Monasterio, Pisa, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aimo%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alberto Aimo</span></a>
</div>
</div>
<sup>c,</sup><sup>d</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vergaro%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Giuseppe Vergaro</span></a><div hidden="hidden" id="id14">
<h3>
<span class="name western">Giuseppe Vergaro</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>c</sup>Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Pisa, Italy</div>
<div class="p">
<sup>d</sup>Fondazione Toscana Gabriele Monasterio, Pisa, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vergaro%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Giuseppe Vergaro</span></a>
</div>
</div>
<sup>c,</sup><sup>d</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22De%20Michieli%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Laura De Michieli</span></a><div hidden="hidden" id="id15">
<h3>
<span class="name western">Laura De Michieli</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>h</sup>Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22De%20Michieli%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Laura De Michieli</span></a>
</div>
</div>
<sup>h</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rauf%20MU%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Muhammad U Rauf</span></a><div hidden="hidden" id="id16">
<h3>
<span class="name western">Muhammad U Rauf</span>, <span class="degrees">MBBS</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rauf%20MU%22%5BAuthor%5D" class="usa-link"><span class="name western">Muhammad U Rauf</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Patel%20RK%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Rishi K Patel</span></a><div hidden="hidden" id="id17">
<h3>
<span class="name western">Rishi K Patel</span>, <span class="degrees">MBBS, BSc</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Patel%20RK%22%5BAuthor%5D" class="usa-link"><span class="name western">Rishi K Patel</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Villanueva%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Eugenia Villanueva</span></a><div hidden="hidden" id="id18">
<h3>
<span class="name western">Eugenia Villanueva</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Villanueva%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Eugenia Villanueva</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lustig%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Yael Lustig</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Yael Lustig</span></h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lustig%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yael Lustig</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Venneri%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Lucia Venneri</span></a><div hidden="hidden" id="id20">
<h3>
<span class="name western">Lucia Venneri</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Venneri%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lucia Venneri</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Martinez-Naharro%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Ana Martinez-Naharro</span></a><div hidden="hidden" id="id21">
<h3>
<span class="name western">Ana Martinez-Naharro</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Martinez-Naharro%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ana Martinez-Naharro</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lachmann%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id22"><span class="name western">Helen Lachmann</span></a><div hidden="hidden" id="id22">
<h3>
<span class="name western">Helen Lachmann</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lachmann%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Helen Lachmann</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wechalekar%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id23"><span class="name western">Ashutosh Wechalekar</span></a><div hidden="hidden" id="id23">
<h3>
<span class="name western">Ashutosh Wechalekar</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wechalekar%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ashutosh Wechalekar</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Whelan%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id24"><span class="name western">Carol Whelan</span></a><div hidden="hidden" id="id24">
<h3>
<span class="name western">Carol Whelan</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Whelan%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Carol Whelan</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Petrie%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id25"><span class="name western">Aviva Petrie</span></a><div hidden="hidden" id="id25">
<h3>
<span class="name western">Aviva Petrie</span>, <span class="degrees">MSc</span>
</h3>
<div class="p">
<sup>k</sup>University College London, Biostatistics Unit, UCL Eastman Dental Institute, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Petrie%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Aviva Petrie</span></a>
</div>
</div>
<sup>k</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hawkins%20PN%22%5BAuthor%5D" class="usa-link" aria-describedby="id26"><span class="name western">Philip N Hawkins</span></a><div hidden="hidden" id="id26">
<h3>
<span class="name western">Philip N Hawkins</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hawkins%20PN%22%5BAuthor%5D" class="usa-link"><span class="name western">Philip N Hawkins</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Solomon%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id27"><span class="name western">Scott Solomon</span></a><div hidden="hidden" id="id27">
<h3>
<span class="name western">Scott Solomon</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>l</sup>Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Solomon%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Scott Solomon</span></a>
</div>
</div>
<sup>l</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gillmore%20JD%22%5BAuthor%5D" class="usa-link" aria-describedby="id28"><span class="name western">Julian D Gillmore</span></a><div hidden="hidden" id="id28">
<h3>
<span class="name western">Julian D Gillmore</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gillmore%20JD%22%5BAuthor%5D" class="usa-link"><span class="name western">Julian D Gillmore</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fontana%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id29"><span class="name western">Marianna Fontana</span></a><div hidden="hidden" id="id29">
<h3>
<span class="name western">Marianna Fontana</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fontana%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marianna Fontana</span></a>
</div>
</div>
<sup>a,</sup><sup>∗</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>a</sup>National Amyloidosis Centre, University College London, London, United Kingdom</div>
<div id="aff2">
<sup>b</sup>Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy</div>
<div id="aff3">
<sup>c</sup>Health Science Interdisciplinary Center, Scuola Superiore Sant’Anna, Pisa, Italy</div>
<div id="aff4">
<sup>d</sup>Fondazione Toscana Gabriele Monasterio, Pisa, Italy</div>
<div id="aff5">
<sup>e</sup>Division of Cardiology, Department of Internal Medicine, Medical University of Vienna, Vienna, Austria</div>
<div id="aff6">
<sup>f</sup>Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy</div>
<div id="aff7">
<sup>g</sup>OHSU Center for Hypertrophic Cardiomyopathy and Amyloidosis, Portland, Oregon, USA</div>
<div id="aff8">
<sup>h</sup>Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy</div>
<div id="aff9">
<sup>i</sup>Cardiology Unit, University Hospital Padua, Padua, Italy</div>
<div id="aff10">
<sup>j</sup>Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy</div>
<div id="aff11">
<sup>k</sup>University College London, Biostatistics Unit, UCL Eastman Dental Institute, London, United Kingdom</div>
<div id="aff12">
<sup>l</sup>Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA</div>
<div class="author-notes p"><div class="fn" id="cor1">
<sup>∗</sup><p class="display-inline"><strong>Address for correspondence:</strong> Dr Marianna Fontana, National Amyloidosis Centre, University College London, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, United Kingdom. <span>m.fontana@ucl.ac.uk</span></p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2023 Dec 13; Revised 2023 Dec 26; Accepted 2023 Dec 28.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2024 The Authors</div>
<p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC11004588  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38530684/" class="usa-link">38530684</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abs0010"><h2>Abstract</h2>
<section id="sec1_pmc"><h3 class="pmc_sec_title">Background</h3>
<p>Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cardiomyopathy. The clinical course varies among individuals and there are no established measures to assess disease progression.</p></section><section id="sec2_pmc"><h3 class="pmc_sec_title">Objectives</h3>
<p>The goal of this study was to assess the prognostic importance of an increase in N-terminal pro–B-type natriuretic peptide (NT-proBNP) and outpatient diuretic intensification (ODI) as markers of disease progression in a large cohort of patients with ATTR-CA.</p></section><section id="sec3_pmc"><h3 class="pmc_sec_title">Methods</h3>
<p>We evaluated landmark survival analysis based on worsening of NT-proBNP and requirement for ODI between time of diagnosis and a 1-year visit, and subsequent mortality in 2,275 patients with ATTR-CA from 7 specialist centers. The variables were developed in the National Amyloidosis Centre (NAC) cohort (n = 1,598) and validated in the external cohort from the remaining centers (n = 677).</p></section><section id="sec4_pmc"><h3 class="pmc_sec_title">Results</h3>
<p>Between baseline and 1-year visits, 551 (34.5%) NAC patients and 204 (30.1%) patients in the external validation cohort experienced NT-proBNP progression (NT-proBNP increase &gt;700 ng/L and &gt;30%), which was associated with mortality (NAC cohort: HR: 1.82; 95% CI: 1.57-2.10; <em>P</em> &lt; 0.001; validation cohort: HR: 1.75; 95% CI: 1.32-2.33; <em>P</em> &lt; 0.001). At 1 year, 451 (28.2%) NAC patients and 301 (44.5%) patients in the external validation cohort experienced ODI, which was associated with mortality (NAC cohort: HR: 1.88; 95% CI: 1.62-2.18; <em>P</em> &lt; 0.001; validation cohort: HR: 2.05; 95% CI: 1.53-2.74; <em>P</em> &lt; 0.001). When compared with patients with a stable NT-proBNP and stable diuretic dose, a higher risk of mortality was observed in those experiencing either NT-proBNP progression or ODI (NAC cohort: HR: 1.93; 95% CI: 1.65-2.27; <em>P</em> &lt; 0.001; validation cohort: HR: 1.94; 95% CI: 1.36-2.77; <em>P</em> &lt; 0.001), and those experiencing both NT-proBNP progression and ODI (NAC cohort: HR: 2.98; 95% CI: 2.42-3.67; <em>P</em> &lt; 0.001; validation cohort: HR: 3.23; 95% CI: 2.17-4.79; <em>P</em> &lt; 0.001).</p></section><section id="sec5"><h3 class="pmc_sec_title">Conclusions</h3>
<p>NT-proBNP progression and ODI are frequent and consistently associated with an increased risk of mortality. Combining both variables produces a simple, universally applicable model that detects disease progression in ATTR-CA.</p></section><section id="kwrds0010" class="kwd-group"><p><strong>Key Words:</strong> cardiac ATTR amyloidosis, disease progression, NT-proBNP, outpatient diuretic intensification</p></section></section><section class="abstract" id="abs0015"><h2>Central Illustration</h2>
<figure class="fig xbox font-sm" id="undfig1"><p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11004588_ga1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e24/11004588/e0d2a240669b/ga1.jpg" loading="lazy" height="874" width="765" alt="graphic file with name ga1.jpg"></a></p>
<div class="p text-right font-secondary"><a href="figure/undfig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section><hr class="headless">
<p id="p0010">Transthyretin cardiac amyloidosis (ATTR-CA), is a progressive and ultimately fatal cardiomyopathy, characterized by the deposition of misfolded transthyretin, in the form of amyloid fibrils, within the myocardial extracellular space.<a href="#bib1" class="usa-link" aria-describedby="bib1"><sup>1</sup></a><sup>,</sup><a href="#bib2" class="usa-link" aria-describedby="bib2"><sup>2</sup></a> The sporadic, noninherited, wild-type (wtATTR-CA) is a condition of older, predominantly male individuals; whereas the hereditary form (hATTR-CA) can present earlier in life with a varying clinical phenotype, often comprising both cardiomyopathy and polyneuropathy.<a href="#bib3" class="usa-link" aria-describedby="bib3"><sup>3</sup></a><sup>,</sup><a href="#bib4" class="usa-link" aria-describedby="bib4"><sup>4</sup></a></p>
<p id="p0015">The only drug currently approved for the treatment of ATTR-CA is tafamidis, which stabilizes the TTR tetramer to prevent dissociation into amyloidogenic monomers that deposit in the myocardium.<a href="#bib5" class="usa-link" aria-describedby="bib5"><sup>5</sup></a> However, several novel compounds that inhibit TTR synthesis and subsequent amyloid formation are in advanced stages of development and likely to become available soon in clinical practice.<a href="#bib6" class="usa-link" aria-describedby="bib6"><sup>6</sup></a> Indicators of worsening disease might highlight the need to switch to alternative agents with different mechanisms of action or consider combination therapy, and will be crucial in guiding treatment decisions. Hence, there is an urgent clinical need to identify widely applicable markers of disease progression. Advances in diagnostic techniques have translated into patients with ATTR-CA being diagnosed at earlier disease stages, with substantially lower mortality. These changes have important implications for clinical trial design and have spurred an increasing need to identify markers of disease progression that could be used alongside traditional endpoints as an extended composite outcome and capture a higher number of events.<a href="#bib7" class="usa-link" aria-describedby="bib7"><sup>7</sup></a></p>
<p id="p0020">An increase in N-terminal pro–B-type natriuretic peptide (NT-proBNP) is common in patients with heart failure who experience disease progression.<a href="#bib8" class="usa-link" aria-describedby="bib8"><sup>8</sup></a> Although an increase in NT-proBNP has been identified as a marker of disease progression in a small cohort of patients with wtATTR-CA, this is yet to be validated and has not been applied to patients with hATTR-CA, or patients prescribed disease-modifying therapy.<a href="#bib9" class="usa-link" aria-describedby="bib9"><sup>9</sup></a> A recent consensus document suggested adopting the NT-proBNP thresholds used to monitor treatment response in cardiac light-chain amyloidosis.<a href="#bib10" class="usa-link" aria-describedby="bib10"><sup>10</sup></a> However, considering the differences in phenotype, prognosis, and treatment paradigm, it is plausible that alternative thresholds are more appropriate in ATTR-CA. In response to disease progression and worsening heart failure symptoms, outpatient diuretic intensification (ODI) is also common and directly affects NT-proBNP levels. ODI is also a strong independent predictor of prognosis in patients with heart failure, but the clinical significance of ODI in patients with ATTR-CA is yet to be characterized.<a href="#bib11" class="usa-link" aria-describedby="bib11">11</a>, <a href="#bib12" class="usa-link" aria-describedby="bib12">12</a>, <a href="#bib13" class="usa-link" aria-describedby="bib13">13</a></p>
<p id="p0025">The aims of this study were to assess the prognostic importance of an increase in NT-proBNP and ODI as markers of disease progression in a large cohort of patients with ATTR-CA.</p>
<section id="sec1"><h2 class="pmc_sec_title">Methods</h2>
<section id="sec1.1"><h3 class="pmc_sec_title">Patient population</h3>
<p id="p0030">This is a retrospective multinational longitudinal study of patients diagnosed with ATTR-CA between 2005 and 2022 from 7 specialist referral centers: National Amyloidosis Centre (UK), Portland, Oregon (USA), Vienna (Austria), and 4 Italian centers (Bologna, Florence, Padua, and Pisa). Patients who underwent a comprehensive assessment at the time of diagnosis, and at 1-year of follow-up were eligible for inclusion. The diagnosis of ATTR-CA was established on the basis of validated diagnostic criteria.<a href="#bib10" class="usa-link" aria-describedby="bib10"><sup>10</sup></a> All patients underwent genetic sequencing of the <em>TTR</em>-gene. The study was conducted according to the Declaration of Helsinki and informed consent was obtained under the institutional review board policies of the relevant hospital administrations.</p></section><section id="sec1.2"><h3 class="pmc_sec_title">Outpatient diuretic intensification</h3>
<p id="p0035">At the time of diagnosis and the subsequent 1-year follow-up assessment, the dose of oral loop diuretic was standardized to furosemide equivalents.<a href="#bib14" class="usa-link" aria-describedby="bib14"><sup>14</sup></a> ODI was defined as any postdiagnosis initiation or increment in the dose of loop diuretic (furosemide equivalent).<a href="#bib11" class="usa-link" aria-describedby="bib11"><sup>11</sup></a><sup>,</sup><a href="#bib12" class="usa-link" aria-describedby="bib12"><sup>12</sup></a></p></section><section id="sec1.3"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="p0040">Statistical analysis was performed using Stata (2021 Stata Statistical Software: Release 17, StataCorp LLC). All continuous variables were tested for normality (Shapiro-Wilk test) and presented as mean ± SD if the distribution was normal or median (Q1-Q3) otherwise. The independent samples Student’s <em>t-</em>test was used to compare means if the data were normally distributed in each group, or its nonparametric equivalent (Mann-Whitney <em>U</em> test) was used to compare the distributions of the 2 groups. Categorical data are presented as absolute numbers (n) and frequencies (%) and compared using the chi-square test.</p>
<p id="p0045">To investigate and validate whether an increase in NT-proBNP and ODI at 1 year were associated with disease progression, the population was separated into a development cohort, comprising the patients from the National Amyloidosis Centre (NAC), and a validation cohort, comprising patients from the remaining centers. The optimal cutpoint for the absolute change in NT-proBNP and percentage change in NT-proBNP at 1 year were established using time-dependent receiver operating characteristic curves in the development cohort. The optimal cutpoint determined by the Youden method for an absolute change was 735 ng/L (sensitivity: 46.4%, specificity: 73.7%), and percentage change was 28.7% (sensitivity: 46.9%, specificity: 61.4%). Cutpoints of an absolute increase &gt;700 ng/L (sensitivity: 47.2%, specificity: 72.5%), and relative percentage increase &gt;30.0% (sensitivity: 46.3%, specificity: 61.9%) were both good discriminators of survival by the log-rank test. Based on the biological variability of NT-proBNP, progression of NT-proBNP was defined as an increase that was both &gt;700 ng/L and &gt;30.0%.<a href="#bib15" class="usa-link" aria-describedby="bib15"><sup>15</sup></a></p>
<p id="p0050">Landmark survival analysis was carried out by assessing the relationship between initiation or intensification of oral diuretic (ODI) or worsening of NT-proBNP at the 1-year follow-up time point, with all-cause mortality from the 1-year follow-up timepoint onward. Mortality data were obtained via national databases. Survival was evaluated using Cox proportional hazards regression analysis, providing estimated HRs with 95% CIs. The proportional hazards assumption was checked and confirmed using weighted Schoenfeld residuals. The association between the variables (NT-proBNP progression and ODI) and mortality was first evaluated in the NAC cohort, and then corroborated using the validation cohort, composed of patients from the remaining centers. Significant results were followed by internal validation. Cox proportional hazards regression analysis was repeated in the whole study population, and internal validation of the model was achieved by performing a bootstrapping procedure with 500 repeats, affording a comparison of the percentile and bias-corrected methods to ensure the results were unbiased.</p>
<p id="p0055">A second landmark analysis comprised patients prescribed disease-modifying therapy or enrolled into clinical trials, who underwent assessment at the start date, and follow-up assessment at 1 year. This assessed the relationship between ODI or NT-proBNP worsening at the 1-year follow-up time point, with all-cause mortality from the 1-year follow-up time point onward.</p>
<p id="p0060">The likelihood ratio test was used to evaluate the contribution of adding ODI to NT-proBNP progression. Harrell’s c-statistic was calculated to measure the discriminatory ability of ODI and NT-proBNP progression. The c-statistics were compared by randomly dividing the data set into 2 cohorts (1:1). The models were fitted to the first cohort, and the c-statistics compared in the second cohort using a Student’s <em>t</em>-test after creating Jackknife standard errors. Kaplan-Meier curves were constructed to view survival in different groups from the 1-year time point. Statistical significance was defined as <em>P</em> &lt; 0.05.</p></section></section><section id="sec2"><h2 class="pmc_sec_title">Results</h2>
<p id="p0065">The total study population comprised 2,275 patients. The development cohort comprised 1,598 patients diagnosed at the NAC, of whom 1,100 (68.8%) had wtATTR-CA, 252 (15.8%) had p.(V142I) hATTR-CA, and 236 (14.8%) had non-p.(V142I) hATTR-CA. The median time from baseline to follow-up assessment was 12.1 months, and the median follow-up duration from the 1-year time point was 32.7 months, during which 183 patients were enrolled into clinical trials and 173 were prescribed disease-modifying therapy (inotersen = 6, patisiran = 93, tafamidis = 74). The validation cohort comprised 677 patients diagnosed at 6 external tertiary referral centers, of whom 608 (89.8%) had wtATTR-CA, 10 (1.5%) had p.(V142I) hATTR-CA, and 59 (8.7%) had non-p.(V142I) hATTR-CA. The median time from baseline to follow-up assessment was 12.5 months, and the median follow-up from the 1-year time point was 22.6 months, during which 68 patients were enrolled into clinical trials (39 of whom were also prescribed tafamidis) and 255 were prescribed disease-modifying therapy (inotersen = 3, patisiran = 5, tafamidis = 247). The baseline characteristics are summarized in <a href="#tbl1" class="usa-link">Table 1</a>.</p>
<section class="tw xbox font-sm" id="tbl1"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Baseline Characteristics for the Study Population</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1">NAC Cohort (N = 1,598)</th>
<th colspan="1" rowspan="1">Wild-Type ATTR-CA Subgroup (n = 1,110)</th>
<th colspan="1" rowspan="1">p.(V142I) hATTR-CA Subgroup<br>(n = 252)</th>
<th colspan="1" rowspan="1">Non-p.(V142I) hATTR-CA Subgroup<br>(n = 236)</th>
<th colspan="1" rowspan="1">External Validation Cohort (n = 677)</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Age, y</td>
<td align="center" colspan="1" rowspan="1">75.7 ± 8.1</td>
<td align="center" colspan="1" rowspan="1">77.8 ± 6.4</td>
<td align="center" colspan="1" rowspan="1">75.2 ± 7.3</td>
<td align="center" colspan="1" rowspan="1">66.2 ± 9.6</td>
<td align="center" colspan="1" rowspan="1">78.4 ± 7.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Male</td>
<td align="center" colspan="1" rowspan="1">1,380 (86.4)</td>
<td align="center" colspan="1" rowspan="1">1,039 (93.6)</td>
<td align="center" colspan="1" rowspan="1">175 (69.4)</td>
<td align="center" colspan="1" rowspan="1">166 (70.3)</td>
<td align="center" colspan="1" rowspan="1">587 (86.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ethnicity</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Caucasian</td>
<td align="center" colspan="1" rowspan="1">1,262 (79.0)</td>
<td align="center" colspan="1" rowspan="1">1,030 (92.8)</td>
<td align="center" colspan="1" rowspan="1">31 (12.3)</td>
<td align="center" colspan="1" rowspan="1">201 (79.0)</td>
<td align="center" colspan="1" rowspan="1">666 (98.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Afro-Caribbean</td>
<td align="center" colspan="1" rowspan="1">308 (19.3)</td>
<td align="center" colspan="1" rowspan="1">73 (6.6)</td>
<td align="center" colspan="1" rowspan="1">213 (84.5)</td>
<td align="center" colspan="1" rowspan="1">22 (9.3)</td>
<td align="center" colspan="1" rowspan="1">11 (1.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Asian</td>
<td align="center" colspan="1" rowspan="1">21 (1.3)</td>
<td align="center" colspan="1" rowspan="1">7 (0.6)</td>
<td align="center" colspan="1" rowspan="1">5 (2.0)</td>
<td align="center" colspan="1" rowspan="1">9 (3.8)</td>
<td align="center" colspan="1" rowspan="1">0 (0.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Other</td>
<td align="center" colspan="1" rowspan="1">7 (0.4)</td>
<td align="center" colspan="1" rowspan="1">0 (0.0)</td>
<td align="center" colspan="1" rowspan="1">3 (1.2)</td>
<td align="center" colspan="1" rowspan="1">4 (1.7)</td>
<td align="center" colspan="1" rowspan="1">0 (0.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">AF/AFL</td>
<td align="center" colspan="1" rowspan="1">776 (48.6)</td>
<td align="center" colspan="1" rowspan="1">612 (55.1)</td>
<td align="center" colspan="1" rowspan="1">97 (38.5)</td>
<td align="center" colspan="1" rowspan="1">67 (28.4)</td>
<td align="center" colspan="1" rowspan="1">374 (55.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">IHD</td>
<td align="center" colspan="1" rowspan="1">287 (18.0)</td>
<td align="center" colspan="1" rowspan="1">239 (21.5)</td>
<td align="center" colspan="1" rowspan="1">34 (13.5)</td>
<td align="center" colspan="1" rowspan="1">14 (5.9)</td>
<td align="center" colspan="1" rowspan="1">147 (21.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diabetes mellitus</td>
<td align="center" colspan="1" rowspan="1">234 (14.6)</td>
<td align="center" colspan="1" rowspan="1">164 (14.8)</td>
<td align="center" colspan="1" rowspan="1">55 (21.8)</td>
<td align="center" colspan="1" rowspan="1">15 (6.4)</td>
<td align="center" colspan="1" rowspan="1">122 (18.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Stroke/TIA</td>
<td align="center" colspan="1" rowspan="1">150 (9.4)</td>
<td align="center" colspan="1" rowspan="1">107 (9.6)</td>
<td align="center" colspan="1" rowspan="1">31 (12.3)</td>
<td align="center" colspan="1" rowspan="1">12 (5.1)</td>
<td align="center" colspan="1" rowspan="1">58 (8.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">CKD stage 3-5</td>
<td align="center" colspan="1" rowspan="1">735 (46.0)</td>
<td align="center" colspan="1" rowspan="1">541 (48.7)</td>
<td align="center" colspan="1" rowspan="1">148 (58.7)</td>
<td align="center" colspan="1" rowspan="1">46 (19.5)</td>
<td align="center" colspan="1" rowspan="1">357 (52.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cardiac devices</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> PPM</td>
<td align="center" colspan="1" rowspan="1">193 (12.1)</td>
<td align="center" colspan="1" rowspan="1">127 (11.4)</td>
<td align="center" colspan="1" rowspan="1">26 (10.3)</td>
<td align="center" colspan="1" rowspan="1">40 (16.9)</td>
<td align="center" colspan="1" rowspan="1">101 (14.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ICD</td>
<td align="center" colspan="1" rowspan="1">37 (2.3)</td>
<td align="center" colspan="1" rowspan="1">26 (2.3)</td>
<td align="center" colspan="1" rowspan="1">6 (2.4)</td>
<td align="center" colspan="1" rowspan="1">5 (2.1)</td>
<td align="center" colspan="1" rowspan="1">22 (3.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CRT-D</td>
<td align="center" colspan="1" rowspan="1">19 (1.2)</td>
<td align="center" colspan="1" rowspan="1">13 (1.2)</td>
<td align="center" colspan="1" rowspan="1">1 (0.4)</td>
<td align="center" colspan="1" rowspan="1">5 (2.1)</td>
<td align="center" colspan="1" rowspan="1">11 (1.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CRT-P</td>
<td align="center" colspan="1" rowspan="1">29 (1.8)</td>
<td align="center" colspan="1" rowspan="1">25 (2.3)</td>
<td align="center" colspan="1" rowspan="1">0 (0.0)</td>
<td align="center" colspan="1" rowspan="1">0 (0.3)</td>
<td align="center" colspan="1" rowspan="1">6 (0.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Heart failure severity</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NYHA functional class</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> I</td>
<td align="center" colspan="1" rowspan="1">220 (13.7)</td>
<td align="center" colspan="1" rowspan="1">153 (13.7)</td>
<td align="center" colspan="1" rowspan="1">11 (4.3)</td>
<td align="center" colspan="1" rowspan="1">57 (24.2)</td>
<td align="center" colspan="1" rowspan="1">142 (21.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> II</td>
<td align="center" colspan="1" rowspan="1">984 (61.6)</td>
<td align="center" colspan="1" rowspan="1">702 (63.2)</td>
<td align="center" colspan="1" rowspan="1">146 (57.9)</td>
<td align="center" colspan="1" rowspan="1">136 (57.6)</td>
<td align="center" colspan="1" rowspan="1">376 (55.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> III</td>
<td align="center" colspan="1" rowspan="1">311 (19.5)</td>
<td align="center" colspan="1" rowspan="1">196 (17.6)</td>
<td align="center" colspan="1" rowspan="1">86 (34.1)</td>
<td align="center" colspan="1" rowspan="1">29 (12.3)</td>
<td align="center" colspan="1" rowspan="1">154 (22.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> IV</td>
<td align="center" colspan="1" rowspan="1">19 (1.2)</td>
<td align="center" colspan="1" rowspan="1">10 (0.9)</td>
<td align="center" colspan="1" rowspan="1">6 (2.3)</td>
<td align="center" colspan="1" rowspan="1">3 (1.3)</td>
<td align="center" colspan="1" rowspan="1">5 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Missing</td>
<td align="center" colspan="1" rowspan="1">63</td>
<td align="center" colspan="1" rowspan="1">49</td>
<td align="center" colspan="1" rowspan="1">3</td>
<td align="center" colspan="1" rowspan="1">11</td>
<td align="center" colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NAC stage</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1</td>
<td align="center" colspan="1" rowspan="1">867 (54.3)</td>
<td align="center" colspan="1" rowspan="1">581 (52.3)</td>
<td align="center" colspan="1" rowspan="1">126 (50.0)</td>
<td align="center" colspan="1" rowspan="1">160 (67.8)</td>
<td align="center" colspan="1" rowspan="1">373 (55.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2</td>
<td align="center" colspan="1" rowspan="1">531 (33.2)</td>
<td align="center" colspan="1" rowspan="1">387 (24.2)</td>
<td align="center" colspan="1" rowspan="1">81 (32.1)</td>
<td align="center" colspan="1" rowspan="1">63 (26.7)</td>
<td align="center" colspan="1" rowspan="1">196 (28.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 3</td>
<td align="center" colspan="1" rowspan="1">200 (12.5)</td>
<td align="center" colspan="1" rowspan="1">142 (12.8)</td>
<td align="center" colspan="1" rowspan="1">45 (17.9)</td>
<td align="center" colspan="1" rowspan="1">13 (5.5)</td>
<td align="center" colspan="1" rowspan="1">108 (15.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NT-proBNP, ng/L</td>
<td align="center" colspan="1" rowspan="1">2,471 (1,309-4,578)</td>
<td align="center" colspan="1" rowspan="1">2,555 (1,423-4,588)</td>
<td align="center" colspan="1" rowspan="1">2,615 (1,488-5,163)</td>
<td align="center" colspan="1" rowspan="1">1,939 (710-3,703)</td>
<td align="center" colspan="1" rowspan="1">2,127 (953-4,439)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> eGFR, mL/min/1.73 m<sup>2</sup>
</td>
<td align="center" colspan="1" rowspan="1">62 (50-77)</td>
<td align="center" colspan="1" rowspan="1">60 (48-74)</td>
<td align="center" colspan="1" rowspan="1">56 (46-68)</td>
<td align="center" colspan="1" rowspan="1">81 (64-90)</td>
<td align="center" colspan="1" rowspan="1">57 (46-73)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Echocardiographic parameters</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> IVSd, mm</td>
<td align="center" colspan="1" rowspan="1">16.7 ± 2.5</td>
<td align="center" colspan="1" rowspan="1">16.8 ± 2.4</td>
<td align="center" colspan="1" rowspan="1">16.9 ± 2.3</td>
<td align="center" colspan="1" rowspan="1">16.2 ± 2.9</td>
<td align="center" colspan="1" rowspan="1">17.8 ± 3.5</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> PWTd, mm</td>
<td align="center" colspan="1" rowspan="1">16.3 ± 2.6</td>
<td align="center" colspan="1" rowspan="1">16.4 ± 2.5</td>
<td align="center" colspan="1" rowspan="1">16.6 ± 2.3</td>
<td align="center" colspan="1" rowspan="1">15.8 ± 2.9</td>
<td align="center" colspan="1" rowspan="1">14.9 ± 5.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> LVEF, %</td>
<td align="center" colspan="1" rowspan="1">48.7 ± 10.5</td>
<td align="center" colspan="1" rowspan="1">49.1 ± 10.1</td>
<td align="center" colspan="1" rowspan="1">44.6 ± 11.1</td>
<td align="center" colspan="1" rowspan="1">51.2 ± 10.7</td>
<td align="center" colspan="1" rowspan="1">52.5 ± 10.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Medications</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Beta-blockers</td>
<td align="center" colspan="1" rowspan="1">868 (54.3)</td>
<td align="center" colspan="1" rowspan="1">633 (57.0)</td>
<td align="center" colspan="1" rowspan="1">157 (62.3)</td>
<td align="center" colspan="1" rowspan="1">78 (33.1)</td>
<td align="center" colspan="1" rowspan="1">389 (57.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ACEI/ARBs</td>
<td align="center" colspan="1" rowspan="1">917 (57.3)</td>
<td align="center" colspan="1" rowspan="1">670 (60.4)</td>
<td align="center" colspan="1" rowspan="1">170 (67.5)</td>
<td align="center" colspan="1" rowspan="1">77 (32.6)</td>
<td align="center" colspan="1" rowspan="1">371 (55.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ARNI</td>
<td align="center" colspan="1" rowspan="1">13 (0.8)</td>
<td align="center" colspan="1" rowspan="1">10 (0.9)</td>
<td align="center" colspan="1" rowspan="1">3 (1.2)</td>
<td align="center" colspan="1" rowspan="1">0 (0.0)</td>
<td align="center" colspan="1" rowspan="1">16 (2.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> MRAs</td>
<td align="center" colspan="1" rowspan="1">650 (40.7)</td>
<td align="center" colspan="1" rowspan="1">450 (40.5)</td>
<td align="center" colspan="1" rowspan="1">142 (56.3)</td>
<td align="center" colspan="1" rowspan="1">58 (24.6)</td>
<td align="center" colspan="1" rowspan="1">225 (33.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> SGT2i</td>
<td align="center" colspan="1" rowspan="1">29 (1.8)</td>
<td align="center" colspan="1" rowspan="1">19 (1.7)</td>
<td align="center" colspan="1" rowspan="1">4 (1.6)</td>
<td align="center" colspan="1" rowspan="1">6 (2.5)</td>
<td align="center" colspan="1" rowspan="1">12 (1.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Loop diuretic</td>
<td align="center" colspan="1" rowspan="1">1,118 (70.0)</td>
<td align="center" colspan="1" rowspan="1">783 (70.5)</td>
<td align="center" colspan="1" rowspan="1">208 (82.5)</td>
<td align="center" colspan="1" rowspan="1">127 (53.8)</td>
<td align="center" colspan="1" rowspan="1">461 (68.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Thiazide diuretic</td>
<td align="center" colspan="1" rowspan="1">67 (4.2)</td>
<td align="center" colspan="1" rowspan="1">44 (4.0)</td>
<td align="center" colspan="1" rowspan="1">17 (6.7)</td>
<td align="center" colspan="1" rowspan="1">6 (2.5)</td>
<td align="center" colspan="1" rowspan="1">43 (6.4)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tspara0015"><p>Values are mean ± SD, n (%), n, or median (Q1-Q3). Patients in the non-p.(V142I) hATTR-CA subgroup had the following variants: p.(Thr80Ala) = 131, p.(Val50Met) = 21, p.(Ser97Tyr) = 16, p.(Ile127Val) = 10, p.(Ile88Leu) = 6, p.(Glu62Asp) = 5, p.(Glu109Lys) = 5, p.(Gly67Val) = 4, p.(Ala117Ser) = 3, p.(Gly26Ser) = 3, p.(Gly67Arg) = 3, p.(Arg54Gly) = 2, p.(Ile127Phe) = 2, p.(Ser43Asn) = 2, p.(Tyr134Cys) = 2, p.(Tyr89Phe) = 2, p.(Ala120Ser) = 1, p.(Asp58Tyr) = 1, p.(Asp58Val) = 1, p.(Cys30Gly) = 1, p.(Glu74Leu) = 1, p.(Glu74Lys) = 1, p.(Glu109Gln) = 1, p.(Glu112Lys) = 1, p.(Gly67Glu) = 1, p.(Gly73Ala) = 1, p.(Gly73Glu) = 1, p.(His110Asp) = 1, p.(Ile93Val) = 1, p.(Ile104Ser) = 1, p.(Ile104Thr) = 1, p.(Phe64Leu) = 1, p.(Ser70Arg) = 1, p.(Tyr116Ser) = 1, p.(Val40Ile) = 1. The external validation cohort comprised 608 patients with wtATTR-CA, 12 patients with p.(V142I) hATTR-CA, and 57 patients with non-p.(V142I) hATTR-CA. Patients with non-p.(V142I) hATTR-CA had the following variants: p.(Ile88Leu) = 26, p.(His128Arg) = 9, p.(Val50Met) = 3, p.(Glu94Gln) = 2, p.(Glu109Gln) = 2, p.(Thr80Ala) = 2, p.(Phe84Leu) = 2, p.(Phe104Ile) = 2, p.(Thr89Ile) = 2, p.(Arg25His) = 1, p.(Glu82Lys) = 1, p.(Glu101Ala) = 1, p.(Gly87Gu) = 1, p.(Gly97Arg) = 1, p.(His130Asn) = 1, p.(Ser97Tyr) = 1.</p></div>
<div class="fn" id="tspara0020"><p>ACEI = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; AFL = atrial flutter; ARB = angiotensin II receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; CKD = chronic kidney disease; CRT-D = cardiac resynchronization therapy defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; eGFR = estimated glomerular filtration rate; hATTR-CA = hereditary transthyretin cardiac amyloidosis; ICD = implantable cardioverter defibrillator; IHD = ischemic heart disease; IVSd = interventricular septum in diastole; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NAC = National Amyloidosis Centre; NT-proBNP = N-terminal pro–B-type natriuretic peptide; PPM = permanent pacemaker; PWTd = posterior wall thickness in diastole; SGLT2i = sodium-glucose cotransporter-2 inhibitor; TIA = transient ischemic attack; wtATTR-CA= wild-type transthyretin cardiac amyloidosis.</p></div>
</div></section><section id="sec2.1"><h3 class="pmc_sec_title">NT-proBNP progression</h3>
<p id="p0070">At 1-year post diagnosis, 551 (34.5%) of NAC patients and 204 (30.1%) of patients in the external validation cohort experienced NT-proBNP progression. In patients who experienced NT-proBNP progression, the median NT-proBNP increased from 2,613 ng/L (Q1-Q3: 1,463-4,604 ng/L) to 4,860 ng/L (Q1-Q3: 3,112-8,822 ng/L). Patients who experienced NT-proBNP progression were older, and had a higher prevalence of p.(V142I) hATTR-CA. Patients who experienced NT-proBNP progression had a greater left ventricular wall thickness and lower estimated glomerular filtration rate than those who did not. Patients who experienced NT-proBNP progression were more commonly prescribed renin-angiotensin system blockers and loop diuretics than those who did not (<a href="#tbl2" class="usa-link">Table 2</a>).</p>
<section class="tw xbox font-sm" id="tbl2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Comparison of Patients Who Experienced NT-proBNP Progression With Those Who Did Not</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th rowspan="2" colspan="1"></th>
<th colspan="3" rowspan="1">NAC Cohort<hr>
</th>
<th colspan="3" rowspan="1">External Validation Cohort<hr>
</th>
</tr>
<tr>
<th colspan="1" rowspan="1">Stable NT-proBNP (n = 1,047, 65.5%)</th>
<th colspan="1" rowspan="1">NT-proBNP Progression (n = 551, 33.5%)</th>
<th colspan="1" rowspan="1">
<em>P</em> Value</th>
<th colspan="1" rowspan="1">Stable NT-proBNP (n = 473, 69.9%)</th>
<th colspan="1" rowspan="1">NT-proBNP Progression (n = 204, 30.1%)</th>
<th colspan="1" rowspan="1">
<em>P</em> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Age, y</td>
<td align="center" colspan="1" rowspan="1">75.2 ± 8.6</td>
<td align="center" colspan="1" rowspan="1">76.6 ± 7.3</td>
<td align="center" colspan="1" rowspan="1">0.004</td>
<td align="center" colspan="1" rowspan="1">77.8 ± 7.7</td>
<td align="center" colspan="1" rowspan="1">79.8 ± 6.6</td>
<td align="center" colspan="1" rowspan="1">0.002</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Male</td>
<td align="center" colspan="1" rowspan="1">900 (86.0)</td>
<td align="center" colspan="1" rowspan="1">480 (87.1)</td>
<td align="center" colspan="1" rowspan="1">0.523</td>
<td align="center" colspan="1" rowspan="1">411 (86.9)</td>
<td align="center" colspan="1" rowspan="1">176 (86.3)</td>
<td align="center" colspan="1" rowspan="1">0.828</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Genotype</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0.433</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Wild type</td>
<td align="center" colspan="1" rowspan="1">737 (70.4)</td>
<td align="center" colspan="1" rowspan="1">373 (67.7)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">422 (89.2)</td>
<td align="center" colspan="1" rowspan="1">186 (91.2)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> p.(V142I)</td>
<td align="center" colspan="1" rowspan="1">138 (13.2)<a href="#tbl2fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">114 (20.7)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">6 (1.3)</td>
<td align="center" colspan="1" rowspan="1">4 (2.0)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Non-p.(V142I)</td>
<td align="center" colspan="1" rowspan="1">172 (16.4)<a href="#tbl2fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">64 (11.6)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">45 (9.5)</td>
<td align="center" colspan="1" rowspan="1">14 (6.9)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">AF/AFL</td>
<td align="center" colspan="1" rowspan="1">522 (49.9)</td>
<td align="center" colspan="1" rowspan="1">254 (46.1)</td>
<td align="center" colspan="1" rowspan="1">0.153</td>
<td align="center" colspan="1" rowspan="1">256 (54.1)</td>
<td align="center" colspan="1" rowspan="1">118 (57.8)</td>
<td align="center" colspan="1" rowspan="1">0.372</td>
</tr>
<tr>
<td colspan="1" rowspan="1">IHD</td>
<td align="center" colspan="1" rowspan="1">191 (18.2)</td>
<td align="center" colspan="1" rowspan="1">96 (17.4)</td>
<td align="center" colspan="1" rowspan="1">0.685</td>
<td align="center" colspan="1" rowspan="1">100 (21.1)</td>
<td align="center" colspan="1" rowspan="1">47 (23.0)</td>
<td align="center" colspan="1" rowspan="1">0.584</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diabetes mellitus</td>
<td align="center" colspan="1" rowspan="1">135 (12.9)</td>
<td align="center" colspan="1" rowspan="1">99 (18.0)</td>
<td align="center" colspan="1" rowspan="1">0.006</td>
<td align="center" colspan="1" rowspan="1">89 (18.8)</td>
<td align="center" colspan="1" rowspan="1">33 (16.2)</td>
<td align="center" colspan="1" rowspan="1">0.412</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Stroke/TIA</td>
<td align="center" colspan="1" rowspan="1">97 (9.3)</td>
<td align="center" colspan="1" rowspan="1">53 (9.6)</td>
<td align="center" colspan="1" rowspan="1">0.817</td>
<td align="center" colspan="1" rowspan="1">41 (8.7)</td>
<td align="center" colspan="1" rowspan="1">17 (8.3)</td>
<td align="center" colspan="1" rowspan="1">0.886</td>
</tr>
<tr>
<td colspan="1" rowspan="1">CKD stage 3-5</td>
<td align="center" colspan="1" rowspan="1">438 (41.8)</td>
<td align="center" colspan="1" rowspan="1">297 (53.9)</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td align="center" colspan="1" rowspan="1">240 (50.7)</td>
<td align="center" colspan="1" rowspan="1">117 (57.4)</td>
<td align="center" colspan="1" rowspan="1">0.114</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cardiac devices</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> PPM</td>
<td align="center" colspan="1" rowspan="1">118 (11.3)</td>
<td align="center" colspan="1" rowspan="1">75 (13.6)</td>
<td align="center" colspan="1" rowspan="1">0.172</td>
<td align="center" colspan="1" rowspan="1">70 (14.8)</td>
<td align="center" colspan="1" rowspan="1">31 (15.2)</td>
<td align="center" colspan="1" rowspan="1">0.894</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ICD</td>
<td align="center" colspan="1" rowspan="1">26 (2.5)</td>
<td align="center" colspan="1" rowspan="1">11 (2.0)</td>
<td align="center" colspan="1" rowspan="1">0.538</td>
<td align="center" colspan="1" rowspan="1">12 (2.5)</td>
<td align="center" colspan="1" rowspan="1">10 (4.9)</td>
<td align="center" colspan="1" rowspan="1">0.111</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CRT-D</td>
<td align="center" colspan="1" rowspan="1">15 (1.4)</td>
<td align="center" colspan="1" rowspan="1">4 (0.7)</td>
<td align="center" colspan="1" rowspan="1">0.215</td>
<td align="center" colspan="1" rowspan="1">6 (1.3)</td>
<td align="center" colspan="1" rowspan="1">5 (2.5)</td>
<td align="center" colspan="1" rowspan="1">0.264</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CRT-P</td>
<td align="center" colspan="1" rowspan="1">18 (1.7)</td>
<td align="center" colspan="1" rowspan="1">11 (2.0)</td>
<td align="center" colspan="1" rowspan="1">0.693</td>
<td align="center" colspan="1" rowspan="1">4 (0.8)</td>
<td align="center" colspan="1" rowspan="1">2 (1.0)</td>
<td align="center" colspan="1" rowspan="1">0.864</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Heart failure severity</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NYHA functional class</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0.022</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0.350</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> I</td>
<td align="center" colspan="1" rowspan="1">160 (15.3)<a href="#tbl2fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">61 (11.1)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">104 (22.0)</td>
<td align="center" colspan="1" rowspan="1">38 (18.6)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> II</td>
<td align="center" colspan="1" rowspan="1">623 (59.5)<a href="#tbl2fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">361 (65.5)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">263 (55.6)</td>
<td align="center" colspan="1" rowspan="1">113 (55.4)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> III</td>
<td align="center" colspan="1" rowspan="1">204 (19.5)</td>
<td align="center" colspan="1" rowspan="1">107 (19.4)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">104 (22.0)</td>
<td align="center" colspan="1" rowspan="1">50 (24.5)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> IV</td>
<td align="center" colspan="1" rowspan="1">16 (1.5)</td>
<td align="center" colspan="1" rowspan="1">3 (0.5)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">2 (0.4)</td>
<td align="center" colspan="1" rowspan="1">3 (1.5)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Missing</td>
<td align="center" colspan="1" rowspan="1">44</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NAC stage</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0.007</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0.460</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1</td>
<td align="center" colspan="1" rowspan="1">597 (57.0)<a href="#tbl2fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">270 (49.0)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">268 (56.7)</td>
<td align="center" colspan="1" rowspan="1">105 (51.5)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2</td>
<td align="center" colspan="1" rowspan="1">331 (31.6)</td>
<td align="center" colspan="1" rowspan="1">200 (36.3)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">132 (27.9)</td>
<td align="center" colspan="1" rowspan="1">64 (31.4)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 3</td>
<td align="center" colspan="1" rowspan="1">119 (11.4)</td>
<td align="center" colspan="1" rowspan="1">81 (14.7)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">73 (15.4)</td>
<td align="center" colspan="1" rowspan="1">35 (17.2)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NT-proBNP, ng/L</td>
<td align="center" colspan="1" rowspan="1">2,291 (1,150-4,482)</td>
<td align="center" colspan="1" rowspan="1">2,732 (1,612-4,717)</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td align="center" colspan="1" rowspan="1">1,984 (854-4,489)</td>
<td align="center" colspan="1" rowspan="1">2,365 (1,090-4,238)</td>
<td align="center" colspan="1" rowspan="1">0.153</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> eGFR, mL/min/1.73 m<sup>2</sup>
</td>
<td align="center" colspan="1" rowspan="1">64 (52-79)</td>
<td align="center" colspan="1" rowspan="1">58 (47-72)</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td align="center" colspan="1" rowspan="1">59 (47-74)</td>
<td align="center" colspan="1" rowspan="1">56 (43-71)</td>
<td align="center" colspan="1" rowspan="1">0.039</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Echocardiographic parameters</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> IVSd, mm</td>
<td align="center" colspan="1" rowspan="1">16.6 ± 2.5</td>
<td align="center" colspan="1" rowspan="1">17.0 ± 2.3</td>
<td align="center" colspan="1" rowspan="1">0.009</td>
<td align="center" colspan="1" rowspan="1">16.6 ± 3.6</td>
<td align="center" colspan="1" rowspan="1">18.2 ± 3.3</td>
<td align="center" colspan="1" rowspan="1">0.021</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> PWTd, mm</td>
<td align="center" colspan="1" rowspan="1">16.2 ± 2.7</td>
<td align="center" colspan="1" rowspan="1">16.6 ± 2.4</td>
<td align="center" colspan="1" rowspan="1">0.011</td>
<td align="center" colspan="1" rowspan="1">14.7 ± 5.6</td>
<td align="center" colspan="1" rowspan="1">15.3 ± 3.3</td>
<td align="center" colspan="1" rowspan="1">0.001</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> LVEF, %</td>
<td align="center" colspan="1" rowspan="1">49.0 ± 10.7</td>
<td align="center" colspan="1" rowspan="1">48.3 ± 10.1</td>
<td align="center" colspan="1" rowspan="1">0.163</td>
<td align="center" colspan="1" rowspan="1">52.7 ± 10.6</td>
<td align="center" colspan="1" rowspan="1">51.9 ± 10.0</td>
<td align="center" colspan="1" rowspan="1">0.275</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Medications</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Beta-blockers</td>
<td align="center" colspan="1" rowspan="1">551 (52.6)</td>
<td align="center" colspan="1" rowspan="1">317 (57.5)</td>
<td align="center" colspan="1" rowspan="1">0.061</td>
<td align="center" colspan="1" rowspan="1">270 (57.1)</td>
<td align="center" colspan="1" rowspan="1">119 (58.3)</td>
<td align="center" colspan="1" rowspan="1">0.763</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ACEI/ARBs</td>
<td align="center" colspan="1" rowspan="1">575 (54.9)</td>
<td align="center" colspan="1" rowspan="1">342 (62.1)</td>
<td align="center" colspan="1" rowspan="1">0.006</td>
<td align="center" colspan="1" rowspan="1">244 (51.6)</td>
<td align="center" colspan="1" rowspan="1">129 (63.2)</td>
<td align="center" colspan="1" rowspan="1">0.005</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ARNI</td>
<td align="center" colspan="1" rowspan="1">12 (1.2)</td>
<td align="center" colspan="1" rowspan="1">1 (0.2)</td>
<td align="center" colspan="1" rowspan="1">0.031</td>
<td align="center" colspan="1" rowspan="1">12 (2.5)</td>
<td align="center" colspan="1" rowspan="1">4 (2.0)</td>
<td align="center" colspan="1" rowspan="1">0.651</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> MRAs</td>
<td align="center" colspan="1" rowspan="1">418 (39.9)</td>
<td align="center" colspan="1" rowspan="1">232 (42.1)</td>
<td align="center" colspan="1" rowspan="1">0.399</td>
<td align="center" colspan="1" rowspan="1">143 (30.2)</td>
<td align="center" colspan="1" rowspan="1">82 (40.2)</td>
<td align="center" colspan="1" rowspan="1">0.012</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> SGT2i</td>
<td align="center" colspan="1" rowspan="1">19 (1.8)</td>
<td align="center" colspan="1" rowspan="1">10 (1.8)</td>
<td align="center" colspan="1" rowspan="1">0.999</td>
<td align="center" colspan="1" rowspan="1">8 (1.7)</td>
<td align="center" colspan="1" rowspan="1">4 (2.0)</td>
<td align="center" colspan="1" rowspan="1">0.807</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Loop diuretic</td>
<td align="center" colspan="1" rowspan="1">701 (67.0)</td>
<td align="center" colspan="1" rowspan="1">417 (75.7)</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td align="center" colspan="1" rowspan="1">304 (64.3)</td>
<td align="center" colspan="1" rowspan="1">158 (77.5)</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Thiazide diuretic</td>
<td align="center" colspan="1" rowspan="1">36 (3.4)</td>
<td align="center" colspan="1" rowspan="1">31 (5.6)</td>
<td align="center" colspan="1" rowspan="1">0.038</td>
<td align="center" colspan="1" rowspan="1">29 (6.1)</td>
<td align="center" colspan="1" rowspan="1">14 (6.9)</td>
<td align="center" colspan="1" rowspan="1">0.720</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tspara0030"><p>Values are mean ± SD, n (%), n, or median (Q1-Q3).</p></div>
<div class="fn" id="tspara0035"><p>Abbreviations as in <a href="#tbl1" class="usa-link">Table 1</a>.</p></div>
<div class="fn" id="tbl2fna">
<sup>a</sup><p class="display-inline" id="ntpara0015"><em>P</em> values for pairwise comparison &lt;0.05.</p>
</div>
</div></section><p id="p0075">In the NAC cohort, patients who experienced NT-proBNP progression had a higher death rate (25.0 deaths per 100 person-years [py]; 95% CI: 22.4-27.8 deaths per 100 py) than those who did not (14.0 deaths per 100 py; 95% CI: 12.8-15.4 deaths per 100 py). NT-proBNP progression was associated with a 1.8-fold higher risk of mortality (HR: 1.82; 95% CI: 1.57-2.10; <em>P</em> &lt; 0.001). The increased risk of mortality associated with NT-proBNP progression was consistent across patients with wtATTR-CA (HR: 1.68; 95% CI: 1.40-2.00; <em>P</em> &lt; 0.001), p.(V142I) hATTR-CA (HR: 1.72; 95% CI: 1.27-2.32; <em>P</em> &lt; 0.001), and non-p.(V142I) hATTR-CA (HR: 2.33; 95% CI: 1.52-3.57; <em>P</em> &lt; 0.001).</p>
<p id="p0080">In the external validation cohort, patients who experienced NT-proBNP progression had a higher death rate (18.4 deaths per 100 py; 95% CI: 14.8-22.9 deaths per 100 py) than those who did not (10.6 deaths per 100 py; 95% CI: 8.8-12.8 deaths per 100 py). NT-proBNP progression was associated with a 1.8-fold higher risk of mortality (HR: 1.75; 95% CI: 1.32-2.33; <em>P</em> &lt; 0.001) (<a href="#fig1" class="usa-link">Figure 1</a>).</p>
<figure class="fig xbox font-sm" id="fig1"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11004588_gr1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e24/11004588/c9c916a77a01/gr1.jpg" loading="lazy" height="921" width="714" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>NT-proBNP Progression and Survival</p>
<p>Landmark Kaplan-Meier curves demonstrating the association between N-terminal pro–B-type natriuretic peptide (NT-proBNP) progression at 1 year and subsequent survival. (A) Overall National Amyloidosis Centre (NAC) cohort, (B) wild-type transthyretin cardiac amyloidosis (wtATTR-CA) subgroup, (C) p.(V142I) hereditary transthyretin cardiac amyloidosis (hATTR-CA), (D) non-p.(V142I) hATTR-CA, and (E) external validation cohort.</p></figcaption></figure><p id="p0085">These findings were confirmed in the internal validation, whereby the association between NT-proBNP progression and mortality was assessed in the whole study population (HR: 1.81; 95% CI: 1.59-2.05; <em>P</em> &lt; 0.001) and the bootstrapped results indicated that the coefficients remained constant across the resamples, suggesting robustness in the association between NT-proBNP progression and mortality. NT-proBNP progression was associated with an increased risk of mortality in patients with NAC stage 1 disease (HR: 2.34; 95% CI: 1.90-2.89; <em>P</em> &lt; 0.001) and NAC stage 2 disease (HR: 1.52; 95% CI: 1.24-1.86; <em>P</em> &lt; 0.001), but not in those with NAC stage 3 disease (HR: 1.29; 95% CI: 0.97-1.72; <em>P</em> = 0.08); however, assessment in this subgroup was limited by the small sample size. Nevertheless, the 95% CI contains values that suggest NT-proBNP progression could be associated with an increased risk of mortality. NT-proBNP progression was also associated with an increased risk of mortality in a subgroup of obese patients and in patients with concomitant atrial fibrillation (<a href="#mmc1" class="usa-link">Supplemental Material</a>).</p>
<p id="p0090">When compared with the NT-proBNP cutoffs recommended in the consensus document, the novel definition of NT-proBNP progression demonstrated improved discrimination in the external validation cohort (Harrell’s c-statistic: 0.53; 95% CI: 0.48-0.59 vs 0.56; 95% CI: 0.50-0.61; <em>P</em> = 0.033). Comparison between the novel definition of NT-proBNP progression and both NT-proBNP cutoffs recommended in the consensus document and cutoffs previously used in patients with wtATTR-CA, demonstrated that the novel definition of NT-proBNP progression produced the most consistent HRs across different genotypes, and across the NAC cohort and the external validation cohort (<a href="#mmc1" class="usa-link">Supplemental Table 1</a>).</p>
<p id="p0095">In the whole study population, 515 patients were prescribed disease-modifying therapy or enrolled into clinical trials; and had assessments at the start date, and 1 year after the start date (<a href="#mmc1" class="usa-link">Supplemental Figure 1</a>). In this subgroup, 131 (25.4%) patients experienced NT-proBNP progression, and patients who experienced NT-proBNP progression had a higher death rate (17.5 deaths per 100 py; 95% CI: 12.5-24.5 deaths per 100 py) than those who did not (5.7 deaths per 100 py; 95% CI: 4.1-8.0 deaths per 100 py). NT-proBNP progression was associated with a 3.0-fold higher risk of mortality (HR: 3.02; 95% CI: 1.87-4.87; <em>P</em> &lt; 0.001) (<a href="#fig2" class="usa-link">Figure 2A</a>).</p>
<figure class="fig xbox font-sm" id="fig2"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11004588_gr2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e24/11004588/62811e4f1056/gr2.jpg" loading="lazy" height="367" width="726" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Disease Progression in Clinical Trials and Disease-Modifying Therapy</p>
<p>Landmark Kaplan-Meier curves demonstrating the association between (A) N-terminal pro–B-type natriuretic peptide (NT-proBNP) progression and (B) outpatient diuretic intensification (ODI) at 1 year, and subsequent survival in patients enrolled into clinical trials or prescribed disease-modifying therapy.</p></figcaption></figure></section><section id="sec2.2"><h3 class="pmc_sec_title">Outpatient diuretic intensification</h3>
<p id="p0100">At 1 year, 451 (28.2%) NAC patients and 301 (44.5%) patients in the external validation cohort experienced ODI. Patients who experienced ODI were older and had a higher prevalence of p.(V142I) hATTR-CA and atrial fibrillation compared with those who did not experience ODI. Patients who experienced ODI had a worse functional capacity as evidenced by NYHA functional class and more severe cardiac phenotype evidenced by a higher median NT-proBNP, and greater wall thickness than those who did not. Among patients receiving loop diuretics the median furosemide dose at baseline was similar between the patients who experienced ODI and those who did not in both the NAC cohort (40 mg [40-80 mg]), and the external validation cohort (40 mg [25-75 mg]) (<a href="#tbl3" class="usa-link">Table 3</a>).</p>
<section class="tw xbox font-sm" id="tbl3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Comparison of Patients Who Experienced Outpatient Diuretic Intensification to Those Who Did Not</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th rowspan="2" colspan="1"></th>
<th colspan="3" rowspan="1">NAC Cohort<hr>
</th>
<th colspan="3" rowspan="1">External Validation Cohort<hr>
</th>
</tr>
<tr>
<th colspan="1" rowspan="1">No ODI (n = 1,147, 71.8%)</th>
<th colspan="1" rowspan="1">ODI (n = 451, 28.2%)</th>
<th colspan="1" rowspan="1">
<em>P</em> Value</th>
<th colspan="1" rowspan="1">No ODI (n = 376, 55.5%)</th>
<th colspan="1" rowspan="1">ODI (n = 301, 44.5%)</th>
<th colspan="1" rowspan="1">
<em>P</em> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Age, y</td>
<td align="center" colspan="1" rowspan="1">75.2 ± 8.5</td>
<td align="center" colspan="1" rowspan="1">76.9 ± 7.1</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td align="center" colspan="1" rowspan="1">77.6 ± 7.9</td>
<td align="center" colspan="1" rowspan="1">79.4 ± 6.7</td>
<td align="center" colspan="1" rowspan="1">0.003</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Male</td>
<td align="center" colspan="1" rowspan="1">979 (85.4)</td>
<td align="center" colspan="1" rowspan="1">401 (88.9)</td>
<td align="center" colspan="1" rowspan="1">0.062</td>
<td align="center" colspan="1" rowspan="1">328 (87.2)</td>
<td align="center" colspan="1" rowspan="1">259 (86.0)</td>
<td align="center" colspan="1" rowspan="1">0.651</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Genotype</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0.252</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Wild type</td>
<td align="center" colspan="1" rowspan="1">785 (68.4)</td>
<td align="center" colspan="1" rowspan="1">325 (72.1)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">341 (90.7)</td>
<td align="center" colspan="1" rowspan="1">267 (88.7)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> p.(V142I)</td>
<td align="center" colspan="1" rowspan="1">168 (14.6)<a href="#tbl3fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">84 (18.6)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">3 (0.8)</td>
<td align="center" colspan="1" rowspan="1">7 (2.3)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Non-p.(V142I)</td>
<td align="center" colspan="1" rowspan="1">194 (16.9)<a href="#tbl3fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">42 (9.3)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">32 (8.5)</td>
<td align="center" colspan="1" rowspan="1">27 (9.0)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">AF/AFL</td>
<td align="center" colspan="1" rowspan="1">539 (47.0)</td>
<td align="center" colspan="1" rowspan="1">237 (52.5)</td>
<td align="center" colspan="1" rowspan="1">0.045</td>
<td align="center" colspan="1" rowspan="1">190 (50.5)</td>
<td align="center" colspan="1" rowspan="1">184 (61.1)</td>
<td align="center" colspan="1" rowspan="1">0.006</td>
</tr>
<tr>
<td colspan="1" rowspan="1">IHD</td>
<td align="center" colspan="1" rowspan="1">192 (16.7)</td>
<td align="center" colspan="1" rowspan="1">95 (21.1)</td>
<td align="center" colspan="1" rowspan="1">0.043</td>
<td align="center" colspan="1" rowspan="1">77 (20.5)</td>
<td align="center" colspan="1" rowspan="1">70 (23.3)</td>
<td align="center" colspan="1" rowspan="1">0.078</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diabetes mellitus</td>
<td align="center" colspan="1" rowspan="1">157 (13.7)</td>
<td align="center" colspan="1" rowspan="1">77 (17.1)</td>
<td align="center" colspan="1" rowspan="1">0.085</td>
<td align="center" colspan="1" rowspan="1">59 (15.7)</td>
<td align="center" colspan="1" rowspan="1">63 (20.9)</td>
<td align="center" colspan="1" rowspan="1">0.114</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Stroke/TIA</td>
<td align="center" colspan="1" rowspan="1">105 (9.2)</td>
<td align="center" colspan="1" rowspan="1">45 (10.0)</td>
<td align="center" colspan="1" rowspan="1">0.611</td>
<td align="center" colspan="1" rowspan="1">33 (8.8)</td>
<td align="center" colspan="1" rowspan="1">25 (8.3)</td>
<td align="center" colspan="1" rowspan="1">0.828</td>
</tr>
<tr>
<td colspan="1" rowspan="1">CKD stage 3-5</td>
<td align="center" colspan="1" rowspan="1">510 (69.4)</td>
<td align="center" colspan="1" rowspan="1">225 (30.6)</td>
<td align="center" colspan="1" rowspan="1">0.050</td>
<td align="center" colspan="1" rowspan="1">189 (50.3)</td>
<td align="center" colspan="1" rowspan="1">168 (55.8)</td>
<td align="center" colspan="1" rowspan="1">0.151</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cardiac devices</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> PPM</td>
<td align="center" colspan="1" rowspan="1">139 (12.1)</td>
<td align="center" colspan="1" rowspan="1">54 (12.0)</td>
<td align="center" colspan="1" rowspan="1">0.936</td>
<td align="center" colspan="1" rowspan="1">62 (16.5)</td>
<td align="center" colspan="1" rowspan="1">39 (13.0)</td>
<td align="center" colspan="1" rowspan="1">0.200</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ICD</td>
<td align="center" colspan="1" rowspan="1">24 (2.1)</td>
<td align="center" colspan="1" rowspan="1">13 (2.9)</td>
<td align="center" colspan="1" rowspan="1">0.345</td>
<td align="center" colspan="1" rowspan="1">12 (3.2)</td>
<td align="center" colspan="1" rowspan="1">10 (3.3)</td>
<td align="center" colspan="1" rowspan="1">0.924</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CRT-D</td>
<td align="center" colspan="1" rowspan="1">12 (1.1)</td>
<td align="center" colspan="1" rowspan="1">6 (1.3)</td>
<td align="center" colspan="1" rowspan="1">0.744</td>
<td align="center" colspan="1" rowspan="1">5 (1.3)</td>
<td align="center" colspan="1" rowspan="1">6 (2.0)</td>
<td align="center" colspan="1" rowspan="1">0.497</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CRT-P</td>
<td align="center" colspan="1" rowspan="1">22 (1.9)</td>
<td align="center" colspan="1" rowspan="1">7 (1.6)</td>
<td align="center" colspan="1" rowspan="1">0.622</td>
<td align="center" colspan="1" rowspan="1">3 (0.8)</td>
<td align="center" colspan="1" rowspan="1">3 (1.0)</td>
<td align="center" colspan="1" rowspan="1">0.784</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Heart failure severity</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NYHA functional class</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0.044</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> I</td>
<td align="center" colspan="1" rowspan="1">174 (15.2)<a href="#tbl3fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">47 (10.4)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">95 (25.3)<a href="#tbl3fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">47 (15.6)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> II</td>
<td align="center" colspan="1" rowspan="1">699 (60.9)</td>
<td align="center" colspan="1" rowspan="1">285 (63.2)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">207 (55.1)</td>
<td align="center" colspan="1" rowspan="1">169 (55.1)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> III</td>
<td align="center" colspan="1" rowspan="1">212 (18.5)</td>
<td align="center" colspan="1" rowspan="1">99 (22.0)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">74 (19.7)<a href="#tbl3fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">80 (26.6)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> IV</td>
<td align="center" colspan="1" rowspan="1">12 (1.0)</td>
<td align="center" colspan="1" rowspan="1">7 (1.6)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0 (0.0)<a href="#tbl3fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">5 (1.7)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Missing</td>
<td align="center" colspan="1" rowspan="1">50</td>
<td align="center" colspan="1" rowspan="1">13</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> NAC stage</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1</td>
<td align="center" colspan="1" rowspan="1">662 (57.7)<a href="#tbl3fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">205 (45.5)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">233 (62.0)<a href="#tbl3fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">140 (46.5)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2</td>
<td align="center" colspan="1" rowspan="1">350 (30.5)<a href="#tbl3fna" class="usa-link"><sup>a</sup></a>
</td>
<td align="center" colspan="1" rowspan="1">181 (40.1)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">88 (23.4)</td>
<td align="center" colspan="1" rowspan="1">108 (35.9)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 3</td>
<td align="center" colspan="1" rowspan="1">135 (11.8)</td>
<td align="center" colspan="1" rowspan="1">65 (14.4)</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">55 (14.6)</td>
<td align="center" colspan="1" rowspan="1">53 (17.6)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">NT-proBNP, ng/L</td>
<td align="center" colspan="1" rowspan="1">2,309 (1,218-4,163)</td>
<td align="center" colspan="1" rowspan="1">3,095 (1,656-5,590)</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td align="center" colspan="1" rowspan="1">1,786 (706-3,697)</td>
<td align="center" colspan="1" rowspan="1">2782 (1,293-5,155)</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">eGFR, mL/min/1.73 m<sup>2</sup>
</td>
<td align="center" colspan="1" rowspan="1">62 (50-77)</td>
<td align="center" colspan="1" rowspan="1">59 (48-76)</td>
<td align="center" colspan="1" rowspan="1">0.062</td>
<td align="center" colspan="1" rowspan="1">60 (47-75)</td>
<td align="center" colspan="1" rowspan="1">57 (44-71)</td>
<td align="center" colspan="1" rowspan="1">0.090</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Echocardiographic parameters</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> IVSd, mm</td>
<td align="center" colspan="1" rowspan="1">16.6 ± 2.5</td>
<td align="center" colspan="1" rowspan="1">17.1 ± 2.3</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td align="center" colspan="1" rowspan="1">17.6 ± 3.7</td>
<td align="center" colspan="1" rowspan="1">18.1 ± 3.2</td>
<td align="center" colspan="1" rowspan="1">0.005</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> PWTd, mm</td>
<td align="center" colspan="1" rowspan="1">16.2 ± 2.7</td>
<td align="center" colspan="1" rowspan="1">16.7 ± 2.2</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
<td align="center" colspan="1" rowspan="1">14.3 ± 3.2</td>
<td align="center" colspan="1" rowspan="1">15.7 ± 6.5</td>
<td align="center" colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> LVEF, %</td>
<td align="center" colspan="1" rowspan="1">49.0 ± 10.5</td>
<td align="center" colspan="1" rowspan="1">48.0 ± 10.3</td>
<td align="center" colspan="1" rowspan="1">0.070</td>
<td align="center" colspan="1" rowspan="1">53.0 ± 10.5</td>
<td align="center" colspan="1" rowspan="1">51.8 ± 10.3</td>
<td align="center" colspan="1" rowspan="1">0.076</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Medications</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Beta-blockers</td>
<td align="center" colspan="1" rowspan="1">607 (52.9)</td>
<td align="center" colspan="1" rowspan="1">261 (57.9)</td>
<td align="center" colspan="1" rowspan="1">0.074</td>
<td align="center" colspan="1" rowspan="1">210 (55.9)</td>
<td align="center" colspan="1" rowspan="1">179 (59.5)</td>
<td align="center" colspan="1" rowspan="1">0.344</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ACEI/ARBs</td>
<td align="center" colspan="1" rowspan="1">664 (57.9)</td>
<td align="center" colspan="1" rowspan="1">253 (56.1)</td>
<td align="center" colspan="1" rowspan="1">0.514</td>
<td align="center" colspan="1" rowspan="1">198 (52.7)</td>
<td align="center" colspan="1" rowspan="1">175 (58.1)</td>
<td align="center" colspan="1" rowspan="1">0.154</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> ARNI</td>
<td align="center" colspan="1" rowspan="1">11 (1.0)</td>
<td align="center" colspan="1" rowspan="1">2 (0.4)</td>
<td align="center" colspan="1" rowspan="1">0.302</td>
<td align="center" colspan="1" rowspan="1">11 (2.9)</td>
<td align="center" colspan="1" rowspan="1">5 (1.7)</td>
<td align="center" colspan="1" rowspan="1">0.282</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> MRAs</td>
<td align="center" colspan="1" rowspan="1">453 (39.5)</td>
<td align="center" colspan="1" rowspan="1">197 (43.7)</td>
<td align="center" colspan="1" rowspan="1">0.125</td>
<td align="center" colspan="1" rowspan="1">125 (33.2)</td>
<td align="center" colspan="1" rowspan="1">100 (33.2)</td>
<td align="center" colspan="1" rowspan="1">0.995</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> SGT2i</td>
<td align="center" colspan="1" rowspan="1">23 (2.0)</td>
<td align="center" colspan="1" rowspan="1">6 (1.3)</td>
<td align="center" colspan="1" rowspan="1">0.363</td>
<td align="center" colspan="1" rowspan="1">7 (1.9)</td>
<td align="center" colspan="1" rowspan="1">5 (1.7)</td>
<td align="center" colspan="1" rowspan="1">0.844</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Loop diuretic</td>
<td align="center" colspan="1" rowspan="1">818 (71.3)</td>
<td align="center" colspan="1" rowspan="1">300 (66.5)</td>
<td align="center" colspan="1" rowspan="1">0.060</td>
<td align="center" colspan="1" rowspan="1">250 (66.5)</td>
<td align="center" colspan="1" rowspan="1">212 (70.4)</td>
<td align="center" colspan="1" rowspan="1">0.274</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Thiazide diuretic</td>
<td align="center" colspan="1" rowspan="1">53 (4.6)</td>
<td align="center" colspan="1" rowspan="1">14 (3.1)</td>
<td align="center" colspan="1" rowspan="1">0.173</td>
<td align="center" colspan="1" rowspan="1">22 (5.9)</td>
<td align="center" colspan="1" rowspan="1">21 (7.0)</td>
<td align="center" colspan="1" rowspan="1">0.543</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tspara0045"><p>Values are mean ± SD, n (%), n, or median (Q1-Q3).</p></div>
<div class="fn" id="tspara0050"><p>ODI = outpatient diuretic intensification; other abbreviations as in <a href="#tbl1" class="usa-link">Table 1</a>.</p></div>
<div class="fn" id="tbl3fna">
<sup>a</sup><p class="display-inline" id="ntpara0010"><em>P</em> values for pairwise comparison &lt;0.05.</p>
</div>
</div></section><p id="p0105">In the NAC cohort, patients who experienced ODI had a higher death rate (26.5 deaths per 100 py; 95% CI: 23.6-29.7 deaths per 100 py) than those who did not (14.3 deaths per 100 py; 95% CI: 13.1-15.7 deaths per 100 py). ODI was associated with a 1.9-fold higher risk of mortality (HR: 1.88; 95% CI: 1.62-2.18; <em>P</em> &lt; 0.001). The associated risk of mortality was dose-dependent, with patients who experienced the greatest degree of ODI having the highest risk of mortality (<a href="#mmc1" class="usa-link">Supplemental Material</a>, <a href="#fig3" class="usa-link">Figure 3</a>). The increased risk of mortality associated with ODI was consistent across patients with wtATTR-CA (HR: 1.76; 95% CI: 1.48-2.11; <em>P</em> &lt; 0.001), p.(V142I) hATTR-CA (HR: 1.47; 95% CI: 1.08-2.01; <em>P</em> = 0.013), and non-p.(V142I) hATTR-CA (HR: 3.65; 95% CI: 2.29-5.81; <em>P</em> &lt; 0.001).</p>
<figure class="fig xbox font-sm" id="fig3"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11004588_gr3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e24/11004588/b15044db43f5/gr3.jpg" loading="lazy" height="1219" width="677" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Degree of ODI and Survival</p>
<p>Landmark Kaplan-Meier curves demonstrating the association between the degree of ODI at 1 year and subsequent survival. (A) Overall NAC cohort. (B) External validation cohort. Abbreviations as in <a href="#fig1" class="usa-link">Figures 1</a> and <a href="#fig2" class="usa-link">2</a>.</p></figcaption></figure><p id="p0110">In the external validation cohort, patients who experienced ODI had a higher death rate (18.0 deaths per 100 py; 95% CI: 15.1-21.7 deaths per 100 py) than those who did not (8.8 deaths per 100 py; 95% CI: 7.0-11.1 deaths per 100 py). ODI was associated with a 2.1-fold higher risk of mortality (HR: 2.05; 95% CI: 1.53-2.74; <em>P</em> &lt; 0.001) (<a href="#fig4" class="usa-link">Figure 4</a>).</p>
<figure class="fig xbox font-sm" id="fig4"><h4 class="obj_head">Figure 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11004588_gr4.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e24/11004588/a7f08932f1c9/gr4.jpg" loading="lazy" height="859" width="715" alt="Figure 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>ODI and Survival</p>
<p>Landmark Kaplan-Meier curves demonstrating the association between ODI at 1 year and subsequent survival. (A) Overall NAC cohort, (B) wtATTR-CA subgroup, (C) p.(V142I) hATTR-CA, (D) non-p.(V142I) hATTR-CA, and (E) external validation cohort. Abbreviations as in <a href="#fig1" class="usa-link">Figures 1</a> and <a href="#fig2" class="usa-link">2</a>.</p></figcaption></figure><p id="p0115">These findings were confirmed in the internal validation, whereby the association between ODI and mortality was assessed in the whole study population (HR: 1.79; 95% CI: 1.58-2.04; <em>P</em> &lt; 0.001), and the bootstrapped results indicated that the coefficients remained constant across the resamples, suggesting robustness in the association between ODI and mortality. ODI was also associated with an increased risk of mortality in patients with NAC stage 1 disease (HR: 1.89; 95% CI: 1.52-2.34; <em>P</em> &lt; 0.001), NAC stage 2 disease (HR: 1.52; 95% CI: 1.25-1.86; <em>P</em> &lt; 0.001), and NAC stage 3 disease (HR: 1.41; 95% CI: 1.07-1.87; <em>P</em> = 0.015).</p>
<p id="p0120">In the whole study population, 515 patients were prescribed disease-modifying therapy or enrolled into clinical trials; and had assessments at the start date, and 1 year after the start date. In this subgroup, 143 (27.7%) patients experienced ODI, and patients who experienced ODI had a higher death rate (16.3 deaths per 100 py; 95% CI: 11.7-22.8 deaths per 100 py) than those who did not (5.9 deaths per 100 py; 95% CI: 4.2-8.2 deaths per 100 py). ODI was associated with a 2.8-fold higher risk of mortality (HR: 2.77; 95% CI: 1.72-4.45; <em>P</em> &lt; 0.001).</p></section><section id="sec2.3"><h3 class="pmc_sec_title">Combined ODI and NT-proBNP progression</h3>
<p id="p0125">In a multivariable analysis with covariates of age and NAC disease stage, both NT-proBNP progression (HR: 1.64; 95% CI: 1.42-1.89; <em>P</em> &lt; 0.001) and ODI (HR: 1.60; 95% CI: 1.38-1.85; <em>P</em> &lt; 0.001) were independently associated with mortality, and this was consistent across patients with wtATTR-CA, p.(V142I) hATTR-CA, and non-p.(V142I) hATTR-CA (<a href="#mmc1" class="usa-link">Supplemental Tables 2</a> and <a href="#mmc1" class="usa-link">3</a>). The likelihood ratio test demonstrated that the addition of NT-proBNP progression to ODI added a significant contribution to the multivariable model (chi-square = 56.36; <em>P</em> &lt; 0.001) and significantly improved the discriminatory ability of the classification compared with ODI alone (Harrell’s c-statistic: 0.61; 95% CI: 0.58-0.64 vs 0.57; 95% CI: 0.55-0.60; <em>P</em> &lt; 0.001).</p>
<p id="p0130">Within the NAC cohort, patients who had a stable NT-proBNP and stable diuretic dose at 1 year had a death rate of 11.5 deaths per 100 py (95% CI: 10.3-13.0 deaths per 100 py), compared with 21.9 deaths per 100 py (95% CI: 19.8-24.4 deaths per 100 py) in patients who experienced either NT-proBNP or ODI progression, and 33.2 deaths per 100 py (95% CI: 28.0-39.3 deaths per 100 py) in patients who experienced both NT-proBNP progression and ODI. Compared with patients with a stable diuretic dose and stable NT-proBNP, those who experienced either NT-proBNP progression or ODI had a 1.9-fold higher risk of mortality (HR: 1.93; 95% CI: 1.65-2.27; <em>P</em> &lt; 0.001), and those who experienced both NT-proBNP progression and ODI had a 3.0-fold higher risk of mortality (HR: 2.98; 95% CI: 2.42-3.67; <em>P</em> &lt; 0.001). When compared with patients who experienced either NT-proBNP progression or ODI, those who experienced both had a 1.5-fold higher risk of mortality (HR: 1.54; 95% CI: 1.26-1.88; <em>P</em> &lt; 0.001). The increased risk of mortality associated with both NT-proBNP progression and ODI was consistent across patients with wtATTR-CA, p.(V142I) hATTR, and non-p.(V142I) hATTR (<a href="#mmc1" class="usa-link">Supplemental Material</a>).</p>
<p id="p0135">In the external validation cohort, patients who had a stable NT-proBNP and stable diuretic dose at 1 year had a death rate of 7.4 deaths per 100 py (95% CI: 5.5-9.92 deaths per 100 py), compared with 14.4 deaths per 100 py (95% CI: 11.7-17.6 deaths per 100 py) in patients who experienced either NT-proBNP progression or ODI, and 23.7 deaths per 100 py (95% CI: 18.1-31.1 deaths per 100 py) in patients who experienced both NT-proBNP progression and ODI. Compared with patients with a stable diuretic dose and stable NT-proBNP, those who experienced either NT-proBNP progression or ODI had a 1.9-fold higher risk of mortality (HR: 1.94; 95% CI: 1.36-2.77; <em>P</em> &lt; 0.001), and those who experienced both NT-proBNP progression and ODI had a 3.2-fold higher risk of mortality (HR: 3.23; 95% CI: 2.17-4.79; <em>P</em> &lt; 0.001). When compared with patients who experienced either NT-proBNP progression or ODI, those who experienced both had a 1.7-fold higher risk of mortality (HR: 1.66; 95% CI: 1.19-2.33; <em>P</em> = 0.003) (<a href="#fig5" class="usa-link">Figure 5</a>).</p>
<figure class="fig xbox font-sm" id="fig5"><h4 class="obj_head">Figure 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11004588_gr5.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e24/11004588/988acc082b1d/gr5.jpg" loading="lazy" height="1018" width="743" alt="Figure 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Combination NT-proBNP Progression and ODI</p>
<p>Landmark Kaplan-Meier curves demonstrating the association between the NT-proBNP progression and ODI at 1 year and subsequent survival. (A) Overall NAC cohort, (B) wtATTR-CA subgroup, (C) p.(V142I) hATTR-CA, (D) non-p.(V142I) hATTR-CA, and (E) external validation cohort. Abbreviations as in <a href="#fig1" class="usa-link">Figures 1</a> and <a href="#fig2" class="usa-link">2</a>.</p></figcaption></figure><p id="p0140">These findings were confirmed in the internal validation, whereby the association between the combined variables and mortality was assessed in the whole study population (stable NT-proBNP and stable diuretic dose vs either NT-proBNP progression or ODI: HR: 1.88; 95% CI: 1.62-2.17; <em>P</em> &lt; 0.001; stable NT-proBNP and stable diuretic dose vs NT-proBNP progression and ODI: HR: 2.88; 95% CI: 2.40-3.45; <em>P</em> &lt; 0.001), and the bootstrapped results indicated that the coefficients remained constant across the resamples, suggesting robustness in the association between the combined variables and mortality. The increased risk of mortality associated with both NT-proBNP progression and ODI was consistent across patients with NAC stage 1, 2, and 3 disease (<a href="#mmc1" class="usa-link">Supplemental Material</a>).</p></section></section><section id="sec3"><h2 class="pmc_sec_title">Discussion</h2>
<p id="p0145">This multicenter longitudinal study of &gt;2,000 patients with ATTR-CA demonstrated that: 1) an increase in NT-proBNP of &gt;700 ng/L and &gt;30% was frequent (1 in 3 patients) and consistently associated with an increased risk of mortality; 2) ODI was similarly frequent (1 in 3 patients) and consistently associated with an increased risk of mortality; and 3) the combination of an increase in NT-proBNP of &gt;700 ng/L and &gt;30%, and ODI enabled further refinement of risk. These results were consistent across the overall population and different genotypes. Both variables are extremely informative on the rate of disease progression and associated prognosis, and therefore could be highly relevant both in clinical practice to stratify disease progression, and as a modifiable endpoint in clinical trials of patients with ATTR-CA.</p>
<p id="p0150">ATTR-CA is an inexorably progressive cardiomyopathy, and patients experience worsening heart failure signs and symptoms throughout the course of the disease. However, rate of disease progression is extremely variable, likely reflecting the complex nature of ATTR-CA. Determinants of disease progression are multifactorial, and depend on the underlying genotype, treatment, and comorbidities, hence there is an urgent need to define the disease course and stratify progression at an individual patient level.<a href="#bib7" class="usa-link" aria-describedby="bib7"><sup>7</sup></a><sup>,</sup><a href="#bib16" class="usa-link" aria-describedby="bib16"><sup>16</sup></a><sup>,</sup><a href="#bib17" class="usa-link" aria-describedby="bib17"><sup>17</sup></a> Since its discovery, NT-proBNP has been widely used in heart failure to stratify risk and as a marker of treatment response, with favorable changes being associated with a reduced risk of adverse cardiovascular events.<a href="#bib8" class="usa-link" aria-describedby="bib8"><sup>8</sup></a> Likewise, changes in NT-proBNP have been used in the assessment of ATTR amyloid-specific disease-modifying therapies. The ATTR-ACT (Transthyretin Amyloidosis Cardiomyopathy Clinical Trial), ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloidosis Cardiomyopathy) trial, and APOLLO-B (A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy [ATTR Amyloidosis With Cardiomyopathy]) trial demonstrated that tafamidis, acoramidis, and patisiran, respectively, were all associated with a smaller increase in NT-proBNP compared with placebo.<a href="#bib5" class="usa-link" aria-describedby="bib5"><sup>5</sup></a><sup>,</sup><a href="#bib18" class="usa-link" aria-describedby="bib18"><sup>18</sup></a><sup>,</sup><a href="#bib19" class="usa-link" aria-describedby="bib19"><sup>19</sup></a> However, there is no NT-proBNP cutoff that can be used at an individual patient level to stratify disease progression across all genotypes. The cutoffs used in a small cohort of patients with wtATTR-CA are yet to be validated or applied to patients with hATTR-CA, or patients prescribed disease-modifying therapy, whereas the cutoffs proposed in a recent consensus document are not supported by data from patients with ATTR-CA.<a href="#bib9" class="usa-link" aria-describedby="bib9"><sup>9</sup></a><sup>,</sup><a href="#bib10" class="usa-link" aria-describedby="bib10"><sup>10</sup></a></p>
<p id="p0155">The current study established that NT-proBNP progression (defined as an absolute increase &gt;700 ng/L and relative increase &gt;30%) at 1 year was frequent, occurring in roughly one-third of patients at the NAC, and roughly one-third of patients in the external validation cohort. NT-proBNP progression was more frequent in patients prescribed renin-angiotensin system blockers and loop diuretics, possibly reflecting more advanced cardiac disease at diagnosis.<a href="#bib16" class="usa-link" aria-describedby="bib16"><sup>16</sup></a> NT-proBNP progression was consistently associated with a 1.8-fold higher risk of mortality in both cohorts, and the subgroup of patients with concomitant atrial fibrillation. NT-proBNP progression conferred the highest risk in patients with non-p.(V142I) hATTR-CA, and lowest risk in patients with p.(V142I) hATTR-CA. When compared with the thresholds recommended in the most recent consensus document and the cutoff proposed for patients with wtATTR-CA,<a href="#bib9" class="usa-link" aria-describedby="bib9"><sup>9</sup></a><sup>,</sup><a href="#bib10" class="usa-link" aria-describedby="bib10"><sup>10</sup></a> our novel definition of NT-proBNP progression demonstrated improved discrimination and remarkable consistency with regard to HRs across the NAC cohort and external validation cohort. The novel thresholds were associated with an increased risk of mortality in all 3 genotypes, and also identified patients at an increased risk despite being prescribed disease-modifying therapy or enrolled into clinical trials. These results should support the widespread adoption of these NT-proBNP cutoffs to identify patients experiencing disease progression.</p>
<p id="p0160">Worsening heart failure is often handled in the outpatient setting with intensification of loop diuretic therapy. ODI is frequent in patients with ATTR-CA, with more than one-quarter of patients at the NAC and almost one-half of the external validation cohort experiencing ODI in the first year after diagnosis.<a href="#bib11" class="usa-link" aria-describedby="bib11"><sup>11</sup></a><sup>,</sup><a href="#bib12" class="usa-link" aria-describedby="bib12"><sup>12</sup></a> ODI was associated with a 1.9-fold higher risk of mortality in the overall NAC cohort, and 2.1-fold higher risk of mortality in the external validation cohort, hence confirming the remarkable consistency with regard to associated risk across multiple international specialist centers, in spite of possible differences in individual clinical practices and the propensity to escalate diuretic therapy. The associated risk varied among the genotypes, and ranged from a 1.5-fold higher risk in patients with p.(V142I) hATTR-CA to a 3.7-fold higher risk in patients with non-p.(V142I) hATTR-CA. The observed differences are probably related to differences in the cardiac phenotype, with the p.(V142I) genotype being associated with more advanced and rapidly progressive cardiac disease, whereas patients with non-p.(V142I) hATTR present with a milder cardiac phenotype.<a href="#bib7" class="usa-link" aria-describedby="bib7"><sup>7</sup></a> NT-proBNP progression and ODI occur less frequently in patients with a milder cardiac phenotype, compared with patients with more advanced disease. Therefore, these markers possibly provide a more specific signal that is more representative of disease progression in patients with milder disease. This is supported by the associated risk being highest in patients with NAC stage 1 (mild) disease, and lowest risk in patients with NAC stage 3 (severe) disease.</p>
<p id="p0165">In the setting of ATTR-CA, multiple underlying pathophysiological processes are responsible for the elevation of serum NT-proBNP, including direct cardiac amyloid infiltration, neurohormonal activation, renal filtration, and fluid status, and this forms the basis of the strong prognostic significance of NT-proBNP in cardiac amyloidosis.<a href="#bib20" class="usa-link" aria-describedby="bib20"><sup>20</sup></a> In response to disease progression, ODI is frequent and strongly associated with mortality, but also influences NT-proBNP levels, with a variable response in different individuals, ranging from reduction, to stabilization or increase in NT-proBNP.<a href="#bib13" class="usa-link" aria-describedby="bib13"><sup>13</sup></a> Therefore, the combination of the presence or absence of diuretic intensification and change in NT-proBNP provides incremental information compared with each individual variable, and allows further refinement of the risk of mortality (<a href="#fig6" class="usa-link">Central Illustration</a>). Despite recent advances in diagnostics that have resulted in most patients being diagnosed earlier in the disease process, a significant proportion are still diagnosed with advanced cardiac disease.<a href="#bib7" class="usa-link" aria-describedby="bib7"><sup>7</sup></a> Although both NT-proBNP progression and ODI confer the highest risk in patients with milder cardiac disease, importantly the combination of these variables remains associated with an increased risk of mortality across the spectrum of disease severity.</p>
<figure class="fig xbox font-sm" id="fig6"><h3 class="obj_head">Central Illustration.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11004588_gr6.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e24/11004588/e0d2a240669b/gr6.jpg" loading="lazy" height="874" width="765" alt="Central Illustration"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>N-Terminal Pro–B-Type Natriuretic Peptide Progression and Outpatient Diuretic Intensification Detect Disease Progression</p>
<p>N-terminal pro-B-type natriuretic peptide (NT-proBNP) progression and outpatient diuretic intensification (ODI) are associated with an increased risk of mortality. Combining both variables produces a simple, universally applicable model that detects disease progression in the National Amyloidosis Centre (NAC) and external validation cohorts.</p></figcaption></figure><p id="p0170">Considering the rapidly evolving therapeutic landscape, where several novel compounds are likely to become available, there remains an unmet clinical need to define markers of disease progression. Troponin-T progression (defined as an increase &gt;10 ng/L and &gt;20%) was associated with mortality in a subgroup of patients who had serial measurements at baseline and 1 year (<a href="#mmc1" class="usa-link">Supplemental Figures 2 and 3</a>); however, the widespread use of troponin as a marker of disease progression is significantly limited by the current worldwide use of multiple different troponin assays, with different specialist centers favoring different assays.<a href="#bib20" class="usa-link" aria-describedby="bib20"><sup>20</sup></a> Serial echocardiographic assessments lack the precision to track disease progression, and although worsening stroke volume and mitral and tricuspid regurgitation are associated with mortality, these parameters are challenging to quantify, and subject to significant intraobserver and interobserver variability.<a href="#bib21" class="usa-link" aria-describedby="bib21"><sup>21</sup></a> Although cardiac magnetic resonance with multiparametric mapping has demonstrated utility in tracking treatment response in cardiac light-chain amyloidosis, this imaging modality is costly, only available in highly specialized centers, and cannot be used in patients with cardiac devices.<a href="#bib22" class="usa-link" aria-describedby="bib22"><sup>22</sup></a><sup>,</sup><a href="#bib23" class="usa-link" aria-describedby="bib23"><sup>23</sup></a> The identification of NT-proBNP progression and ODI as surrogate markers of disease progression in ATTR-CA is of great importance. Because of their simplicity, lack of operator variability, wide availability, and universal applicability across genotypes, these novel measures of disease progression could easily be applied to clinical practice with significant implications in terms of guiding optimization of treatment strategies, and also as potential endpoints in clinical trials. NT-proBNP progression and ODI are common occurrences in ATTR-CA, and their inclusion may lead to an important increment in event rates, which could in turn influence contemporary trial design, with fewer patients and a reduced follow-up duration being required to evaluate the efficacy of novel agents.</p>
<section id="sec3.1"><h3 class="pmc_sec_title">Study limitations</h3>
<p id="p0175">There is a survival bias in that this study only included patients with follow-up 1 year after diagnosis, and therefore it may be that the extent of differences is underestimated, and rapid disease progression may have resulted in death before the follow-up assessment. There is a possible selection bias as patients who were too unwell to attend an assessment would not have been included. Inclusion was limited to specialist referral centers, and therefore validation of these markers in a community or general cardiology setting is important. The definition of ODI was limited to new initiation or dose increase of loop diuretics, as they represent the mainstay of volume control in heart failure. Augmentation using thiazide diuretics was not considered, given inherent limitations in dose conversion between loop and nonloop diuretics.</p></section></section><section id="sec4"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="p0180">In this large cohort of patients with ATTR-CA, NT-proBNP progression and ODI were frequent and consistently associated with an increased risk of mortality. Combining both variables produces a simple, universally applicable model that detects disease progression. NT-proBNP progression and ODI represent novel outcomes that, if included in contemporary clinical trials, could allow the capture of more clinically meaningful and potentially modifiable events at earlier stages of disease.</p>
<section class="bt xbox font-sm" id="dtbox1"><h3 class="obj_head">Perspectives.</h3>
<p id="p0185"><strong>COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS:</strong> Elevation of plasma NT-proBNP and ODI in patients with cardiac ATTR amyloidosis are associated with disease progression and increased mortality.</p>
<p id="p0190"><strong>TRANSLATIONAL OUTLOOK:</strong> Incorporation of NT-proBNP progression and ODI in clinical studies could facilitate earlier recognition of clinically meaningful and potentially modifiable events in patients with cardiac ATTR amyloidosis.</p></section></section><section id="sec17"><h2 class="pmc_sec_title">Funding Support and Author Disclosures</h2>
<p id="p0195">Dr Fontana is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/21/33447); and has received consulting income from Intellia, Novo Nordisk, Pfizer, Eidos, Prothena, Akcea, Alnylam, Caleum, Alexion, Janssen, Ionis, and AstraZeneca. Dr Gilmore has received consulting income from Ionis, Eidos, Intellia, Alnylam, and Pfizer. Dr Wechalekar has received consulting income from Alexia, AstraZeneca, Janssen, Attralus, and Prothena. Dr Cappelli has received consulting income from Alnylam, Pfizer, AstraZeneca, Bridgebio, and Novo Nordisk. Dr Cipriani has received consulting income from AstraZeneca. Dr Solomon has received research grants from Alexion, Alnylam, AstraZeneca, Bellerophon, Bayer, BMS, Cytokinetics, Eidos, Gossamer, GSK, Ionis, Lilly, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and has served as a consultant for Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="d36e1981"><p id="ntpara1011"><a href="http://www.onlinejacc.org/podcasts" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer"><strong>Listen to this manuscript's audio summary by Editor-in-Chief Dr Valentin Fuster on</strong></a><a href="https://www.jacc.org/journal/jacc" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer"><strong>www.jacc.org/journal/jacc</strong></a>.</p></div>
<div class="fn p" id="d36e1988"><p id="ntpara0015aa">The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the <a href="https://www.jacc.org/author-center" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Author Center</a>.</p></div>
<div class="fn p" id="appsec2">
<p>Appendix</p>
<p id="p0205">For supplemental material, figures, and tables, please see the online version of this paper.</p>
</div>
</div></section><section id="appsec1"><h2 class="pmc_sec_title">Appendix</h2>
<section class="sm xbox font-sm" id="mmc1"><div class="caption p"><span>Supplementary Material</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11004588/bin/mmc1.docx" data-ga-action="click_feat_suppl" class="usa-link">mmc1.docx</a><sup> (405.2KB, docx) </sup>
</div></div></section></section><section id="cebib0010" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="cebib0010_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="bib1">
<span class="label">1.</span><cite>Ioannou A., Patel R.K., Razvi Y., et al.  Multi-imaging characterization of cardiac phenotype in different types of amyloidosis. J Am Coll Cardiol Img. 2022;14:464–477.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Am%20Coll%20Cardiol%20Img&amp;title=Multi-imaging%20characterization%20of%20cardiac%20phenotype%20in%20different%20types%20of%20amyloidosis&amp;author=A.%20Ioannou&amp;author=R.K.%20Patel&amp;author=Y.%20Razvi&amp;volume=14&amp;publication_year=2022&amp;pages=464-477&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib2">
<span class="label">2.</span><cite>Ruberg F.L., Grogan M., Hanna M., et al.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:2872. doi: 10.1016/j.jacc.2019.04.003.</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6724183/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31171094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Am%20Coll%20Cardiol&amp;title=Transthyretin%20Amyloid%20Cardiomyopathy:%20JACC%20State-of-the-Art%20Review&amp;author=F.L.%20Ruberg&amp;author=M.%20Grogan&amp;author=M.%20Hanna&amp;volume=73&amp;publication_year=2019&amp;pages=2872&amp;pmid=31171094&amp;doi=10.1016/j.jacc.2019.04.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib3">
<span class="label">3.</span><cite>Porcari A., Razvi Y., Masi A., et al.  Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2023;25:515–524. doi: 10.1002/ejhf.2776.</cite> [<a href="https://doi.org/10.1002/ejhf.2776" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36644836/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Prevalence,%20characteristics%20and%20outcomes%20of%20older%20patients%20with%20hereditary%20versus%20wild-type%20transthyretin%20amyloid%20cardiomyopathy&amp;author=A.%20Porcari&amp;author=Y.%20Razvi&amp;author=A.%20Masi&amp;volume=25&amp;publication_year=2023&amp;pages=515-524&amp;pmid=36644836&amp;doi=10.1002/ejhf.2776&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib4">
<span class="label">4.</span><cite>Patel R.K., Ioannou A., Razvi Y., et al.  Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis. Eur J Heart Fail. 2022;24:2355–2363. doi: 10.1002/ejhf.2646.</cite> [<a href="https://doi.org/10.1002/ejhf.2646" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10087683/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36575133/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Sex%20differences%20among%20patients%20with%20transthyretin%20amyloid%20cardiomyopathy%20%E2%80%93%20from%20diagnosis%20to%20prognosis&amp;author=R.K.%20Patel&amp;author=A.%20Ioannou&amp;author=Y.%20Razvi&amp;volume=24&amp;publication_year=2022&amp;pages=2355-2363&amp;pmid=36575133&amp;doi=10.1002/ejhf.2646&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib5">
<span class="label">5.</span><cite>Maurer M.S., Schwartz J.H., Gundapaneni B., et al.  Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–1016. doi: 10.1056/NEJMoa1805689.</cite> [<a href="https://doi.org/10.1056/NEJMoa1805689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30145929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%C2%A0Engl%20J%20Med&amp;title=Tafamidis%20treatment%20for%20patients%20with%20transthyretin%20amyloid%20cardiomyopathy&amp;author=M.S.%20Maurer&amp;author=J.H.%20Schwartz&amp;author=B.%20Gundapaneni&amp;volume=379&amp;publication_year=2018&amp;pages=1007-1016&amp;pmid=30145929&amp;doi=10.1056/NEJMoa1805689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib6">
<span class="label">6.</span><cite>Ioannou A., Fontana M., Gillmore J.D. RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs. 2023;37:127–142. doi: 10.1007/s40259-023-00577-7.</cite> [<a href="https://doi.org/10.1007/s40259-023-00577-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9933836/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36795354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BioDrugs&amp;title=RNA%20targeting%20and%20gene%20editing%20strategies%20for%20transthyretin%20amyloidosis&amp;author=A.%20Ioannou&amp;author=M.%20Fontana&amp;author=J.D.%20Gillmore&amp;volume=37&amp;publication_year=2023&amp;pages=127-142&amp;pmid=36795354&amp;doi=10.1007/s40259-023-00577-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib7">
<span class="label">7.</span><cite>Ioannou A., Patel R.K., Razvi Y., et al.  Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation. 2022;146:1657–1670. doi: 10.1161/CIRCULATIONAHA.122.060852.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.122.060852" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9698091/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36325894/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Impact%20of%20earlier%20diagnosis%20in%20cardiac%20ATTR%20amyloidosis%20over%20the%20course%20of%2020%20years&amp;author=A.%20Ioannou&amp;author=R.K.%20Patel&amp;author=Y.%20Razvi&amp;volume=146&amp;publication_year=2022&amp;pages=1657-1670&amp;pmid=36325894&amp;doi=10.1161/CIRCULATIONAHA.122.060852&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib8">
<span class="label">8.</span><cite>Masson S., Latini R., Anand I.S., et al.  Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial) J Am Coll Cardiol. 2008;52:997–1003. doi: 10.1016/j.jacc.2008.04.069.</cite> [<a href="https://doi.org/10.1016/j.jacc.2008.04.069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18786480/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Am%20Coll%20Cardiol&amp;title=Prognostic%20value%20of%20changes%20in%20N-terminal%20pro-brain%20natriuretic%20peptide%20in%20Val-HeFT%20(Valsartan%20Heart%C2%A0Failure%20Trial)&amp;author=S.%20Masson&amp;author=R.%20Latini&amp;author=I.S.%20Anand&amp;volume=52&amp;publication_year=2008&amp;pages=997-1003&amp;pmid=18786480&amp;doi=10.1016/j.jacc.2008.04.069&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib9">
<span class="label">9.</span><cite>Law S., Petrie A., Chacko L., et al.  Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart. 2022;108:474–478. doi: 10.1136/heartjnl-2021-319063.</cite> [<a href="https://doi.org/10.1136/heartjnl-2021-319063" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8899483/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33990410/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heart&amp;title=Change%20in%20N-terminal%20pro-B-type%20natriuretic%20peptide%20at%201%20year%20predicts%20mortality%20in%20wild-type%20transthyretin%20amyloid%20cardiomyopathy&amp;author=S.%20Law&amp;author=A.%20Petrie&amp;author=L.%20Chacko&amp;volume=108&amp;publication_year=2022&amp;pages=474-478&amp;pmid=33990410&amp;doi=10.1136/heartjnl-2021-319063&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib10">
<span class="label">10.</span><cite>Garcia-Pavia P., Bengel F., Brito D., et al.  Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23:895–905. doi: 10.1002/ejhf.2198.</cite> [<a href="https://doi.org/10.1002/ejhf.2198" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8239846/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33915002/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Expert%20consensus%20on%20the%20monitoring%20of%20transthyretin%20amyloid%20cardiomyopathy&amp;author=P.%20Garcia-Pavia&amp;author=F.%20Bengel&amp;author=D.%20Brito&amp;volume=23&amp;publication_year=2021&amp;pages=895-905&amp;pmid=33915002&amp;doi=10.1002/ejhf.2198&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib11">
<span class="label">11.</span><cite>Ferreira J.P., Liu J., Claggett B.L., et al.  Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT. Eur J Heart Fail. 2022;24:378–384. doi: 10.1002/ejhf.2376.</cite> [<a href="https://doi.org/10.1002/ejhf.2376" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34755426/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Outpatient%20diuretic%20intensification%20as%20endpoint%20in%20heart%20failure%20with%20preserved%20ejection%20fraction%20trials:%20an%20analysis%20from%20TOPCAT&amp;author=J.P.%20Ferreira&amp;author=J.%20Liu&amp;author=B.L.%20Claggett&amp;volume=24&amp;publication_year=2022&amp;pages=378-384&amp;pmid=34755426&amp;doi=10.1002/ejhf.2376&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib12">
<span class="label">12.</span><cite>Chatur S., Vaduganathan M., Claggett B.L., et al.  Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial. Circulation. 2023;148:1735–1745. doi: 10.1161/CIRCULATIONAHA.123.066506.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.123.066506" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10664793/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37632455/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Outpatient%20worsening%20among%20patients%20with%20mildly%20reduced%20and%20preserved%20ejection%20fraction%20heart%20failure%20in%20the%20DELIVER%20trial&amp;author=S.%20Chatur&amp;author=M.%20Vaduganathan&amp;author=B.L.%20Claggett&amp;volume=148&amp;publication_year=2023&amp;pages=1735-1745&amp;pmid=37632455&amp;doi=10.1161/CIRCULATIONAHA.123.066506&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib13">
<span class="label">13.</span><cite>Mullens W., Damman K., Harjola V.P., et al.  The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137–155. doi: 10.1002/ejhf.1369.</cite> [<a href="https://doi.org/10.1002/ejhf.1369" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30600580/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=The%20use%20of%20diuretics%20in%20heart%20failure%20with%20congestion%E2%80%94a%20position%20statement%20from%20the%20Heart%C2%A0Failure%20Association%20of%20the%20European%20Society%20of%20Cardiology&amp;author=W.%20Mullens&amp;author=K.%20Damman&amp;author=V.P.%20Harjola&amp;volume=21&amp;publication_year=2019&amp;pages=137-155&amp;pmid=30600580&amp;doi=10.1002/ejhf.1369&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib14">
<span class="label">14.</span><cite>Cheng R.K., Levy W.C., Vasbinder A., et al.  Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. J Am Coll Cardiol CardioOnc. 2020;2:414–424. doi: 10.1016/j.jaccao.2020.06.007.</cite> [<a href="https://doi.org/10.1016/j.jaccao.2020.06.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7561022/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33073249/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Am%20Coll%20Cardiol%20CardioOnc&amp;title=Diuretic%20dose%20and%20NYHA%20functional%20class%20are%20independent%20predictors%20of%20mortality%20in%20patients%20with%20transthyretin%20cardiac%20amyloidosis&amp;author=R.K.%20Cheng&amp;author=W.C.%20Levy&amp;author=A.%20Vasbinder&amp;volume=2&amp;publication_year=2020&amp;pages=414-424&amp;pmid=33073249&amp;doi=10.1016/j.jaccao.2020.06.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib15">
<span class="label">15.</span><cite>Palladini G., Dispenzieri A., Gertz M.A., et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–4549. doi: 10.1200/JCO.2011.37.7614.</cite> [<a href="https://doi.org/10.1200/JCO.2011.37.7614" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23091105/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Clin%20Oncol&amp;title=New%20criteria%20for%20response%20to%20treatment%20in%20immunoglobulin%20light%20chain%20amyloidosis%20based%20on%20free%20light%20chain%20measurement%20and%20cardiac%20biomarkers:%20impact%20on%20survival%20outcomes&amp;author=G.%20Palladini&amp;author=A.%20Dispenzieri&amp;author=M.A.%20Gertz&amp;volume=30&amp;publication_year=2012&amp;pages=4541-4549&amp;pmid=23091105&amp;doi=10.1200/JCO.2011.37.7614&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib16">
<span class="label">16.</span><cite>Ioannou A., Massa P., Patel R.K., et al.  Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023;44:2893–2907. doi: 10.1093/eurheartj/ehad347.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehad347" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10424879/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37216684/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Conventional%20heart%20failure%20therapy%20in%20cardiac%20ATTR%20amyloidosis&amp;author=A.%20Ioannou&amp;author=P.%20Massa&amp;author=R.K.%20Patel&amp;volume=44&amp;publication_year=2023&amp;pages=2893-2907&amp;pmid=37216684&amp;doi=10.1093/eurheartj/ehad347&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib17">
<span class="label">17.</span><cite>Lane T., Fontana M., Martinez-Naharro A., et al.  Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140:16–26. doi: 10.1161/CIRCULATIONAHA.118.038169.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.118.038169" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31109193/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Natural%20history,%20quality%20of%20life,%20and%20outcome%20in%20cardiac%20transthyretin%20amyloidosis&amp;author=T.%20Lane&amp;author=M.%20Fontana&amp;author=A.%20Martinez-Naharro&amp;volume=140&amp;publication_year=2019&amp;pages=16-26&amp;pmid=31109193&amp;doi=10.1161/CIRCULATIONAHA.118.038169&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib18">
<span class="label">18.</span><cite>European Society of Cardiology  Trial demonstrates potential of acoramidis for transthyretin amyloid cardiomyopathy. <a href="https://www.escardio.org/The-ESC/Press-Office/Press-releases/Trial-demonstrates-potential-of-acoramidis-for-transthyretin-amyloid-cardiomyopathy" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.escardio.org/The-ESC/Press-Office/Press-releases/Trial-demonstrates-potential-of-acoramidis-for-transthyretin-amyloid-cardiomyopathy</a></cite>
</li>
<li id="bib19">
<span class="label">19.</span><cite>Maurer M.S., Kale P., Fontana M., et al.  Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389:1553–1565. doi: 10.1056/NEJMoa2300757.</cite> [<a href="https://doi.org/10.1056/NEJMoa2300757" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10757426/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37888916/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%C2%A0Engl%20J%20Med&amp;title=Patisiran%20treatment%20in%20patients%20with%20transthyretin%20cardiac%20amyloidosis&amp;author=M.S.%20Maurer&amp;author=P.%20Kale&amp;author=M.%20Fontana&amp;volume=389&amp;publication_year=2023&amp;pages=1553-1565&amp;pmid=37888916&amp;doi=10.1056/NEJMoa2300757&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib20">
<span class="label">20.</span><cite>Gillmore J.D., Damy T., Fontana M., et al.  A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39:2799–2806. doi: 10.1093/eurheartj/ehx589.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehx589" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29048471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=A%C2%A0new%20staging%20system%20for%20cardiac%20transthyretin%20amyloidosis&amp;author=J.D.%20Gillmore&amp;author=T.%20Damy&amp;author=M.%20Fontana&amp;volume=39&amp;publication_year=2018&amp;pages=2799-2806&amp;pmid=29048471&amp;doi=10.1093/eurheartj/ehx589&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib21">
<span class="label">21.</span><cite>Chacko L., Karia N., Venneri L., et al.  Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022;24:1700–1712. doi: 10.1002/ejhf.2606.</cite> [<a href="https://doi.org/10.1002/ejhf.2606" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10108569/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35779241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Progression%20of%20echocardiographic%20parameters%20and%20prognosis%20in%20transthyretin%20cardiac%20amyloidosis&amp;author=L.%20Chacko&amp;author=N.%20Karia&amp;author=L.%20Venneri&amp;volume=24&amp;publication_year=2022&amp;pages=1700-1712&amp;pmid=35779241&amp;doi=10.1002/ejhf.2606&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib22">
<span class="label">22.</span><cite>Ioannou A., Patel R.K., Martinez-Naharro A., et al.  Tracking multiorgan treatment response in systemic al-amyloidosis with cardiac magnetic resonance derived extracellular volume mapping. J Am Coll Cardiol Img. 2023;16:1038–1052. doi: 10.1016/j.jcmg.2023.02.019.</cite> [<a href="https://doi.org/10.1016/j.jcmg.2023.02.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10406611/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37178079/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%C2%A0Am%20Coll%20Cardiol%20Img&amp;title=Tracking%20multiorgan%20treatment%20response%20in%20systemic%20al-amyloidosis%20with%20cardiac%20magnetic%20resonance%20derived%20extracellular%20volume%20mapping&amp;author=A.%20Ioannou&amp;author=R.K.%20Patel&amp;author=A.%20Martinez-Naharro&amp;volume=16&amp;publication_year=2023&amp;pages=1038-1052&amp;pmid=37178079&amp;doi=10.1016/j.jcmg.2023.02.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib23">
<span class="label">23.</span><cite>Ioannou A., Patel R.K., Martinez-Naharro A., et al.  Tracking treatment response in cardiac light-chain amyloidosis with native T1 mapping. JAMA Cardiol. 2023;8:848–852. doi: 10.1001/jamacardio.2023.2010.</cite> [<a href="https://doi.org/10.1001/jamacardio.2023.2010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10357357/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37466990/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Cardiol&amp;title=Tracking%20treatment%20response%20in%20cardiac%20light-chain%20amyloidosis%20with%20native%20T1%20mapping&amp;author=A.%20Ioannou&amp;author=R.K.%20Patel&amp;author=A.%20Martinez-Naharro&amp;volume=8&amp;publication_year=2023&amp;pages=848-852&amp;pmid=37466990&amp;doi=10.1001/jamacardio.2023.2010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>Supplementary Material</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11004588/bin/mmc1.docx" data-ga-action="click_feat_suppl" class="usa-link">mmc1.docx</a><sup> (405.2KB, docx) </sup>
</div></div></section></section></section></section></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1016/j.jacc.2023.12.036"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/main.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.0 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/11004588/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/11004588/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11004588%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11004588/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11004588/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC11004588/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/38530684/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC11004588/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/38530684/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC11004588/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/11004588/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="3QC7xIlJQUrr2YbihyhVEBwaWdVpx49V4zpO0tJVNgGXmruDvMmBsfYKH1bZaEQz">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
